Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

<!DOCTYPE html> <html lang="en" > <head > <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="HandheldFriendly" content="True" /> <meta name="MobileOptimized" content="320" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <link rel="stylesheet" href="/static/assets/style-70b9163a.css" /> <script type="module" crossorigin="" src="/static/assets/base_style-ec2bc71e.js"></script> <link rel="stylesheet" href="/static/assets/style-ef962842.css" /> <link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" /> <script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script> <style> @media screen and (min-width: 64em) { div.pmc-wm { background: repeat-y; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E"); padding-left: 3rem; } } </style> <link rel="apple-touch-icon" sizes="180x180" href="/static/img/favicons/apple-touch-icon.png" /> <link rel="icon" type="image/png" sizes="48x48" href="/static/img/favicons/favicon-48x48.png" /> <link rel="icon" type="image/png" sizes="32x32" href="/static/img/favicons/favicon-32x32.png" /> <link rel="icon" type="image/png" sizes="16x16" href="/static/img/favicons/favicon-16x16.png" /> <link rel="manifest" href="/static/img/favicons/site.webmanifest" /> <link rel="mask-icon" href="/static/img/favicons/safari-pinned-tab.svg" color="#0071bc" /> <meta name="msapplication-config" content="/static/img/favicons/browserconfig.xml" /> <meta name="theme-color" content="#ffffff" /> <title> Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms - PMC </title>  <meta name="ncbi_app" content="cloudpmc-viewer" /> <meta name="ncbi_db" content="pmc" /> <meta name="ncbi_phid" content="E5FD5BC8741B03F3035BC800156EF0F5.m_1" />  <meta name="ncbi_pdid" content="article" /> <link rel="preconnect" href="https://www.google-analytics.com" /> <link rel="dns-prefetch" href="https://cdn.ncbi.nlm.nih.gov" /> <link rel="preconnect" href="https://code.jquery.com" /> <meta name="ncbi_domain" content="wjco"> <meta name="ncbi_type" content="fulltext"> <meta name="ncbi_pcid" content="journal"> <link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/"> <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"> <meta name="citation_journal_title" content="World Journal of Clinical Oncology"> <meta name="citation_title" content="Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms"> <meta name="citation_author" content="Mihnea-Alexandru Găman"> <meta name="citation_author_institution" content="Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania"> <meta name="citation_author_institution" content="Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania"> <meta name="citation_author_institution" content="Department of Cellular and Molecular Pathology, Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest 030304, Romania"> <meta name="citation_author" content="Bahadar Singh Srichawla"> <meta name="citation_author_institution" content="Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States"> <meta name="citation_author" content="Yong-Feng Chen"> <meta name="citation_author_institution" content="Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China"> <meta name="citation_author" content="Poulami Roy"> <meta name="citation_author_institution" content="Department of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India"> <meta name="citation_author" content="Arkadeep Dhali"> <meta name="citation_author_institution" content="Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom"> <meta name="citation_author" content="Ahmed Nahian"> <meta name="citation_author_institution" content="Lecom at Seton Hill, Greensburg, PA 15601, United States"> <meta name="citation_author" content="Muhammad Romail Manan"> <meta name="citation_author_institution" content="Faculty of Medicine, Services Hospital, Lahore 54000, Pakistan"> <meta name="citation_author" content="Vincent Kipkorir"> <meta name="citation_author_institution" content="Department of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya"> <meta name="citation_author" content="Richard Christian Suteja"> <meta name="citation_author_institution" content="Faculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia"> <meta name="citation_author" content="Lakshmi Venkata Simhachalam Kutikuppala"> <meta name="citation_author_institution" content="Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India"> <meta name="citation_author" content="Amelia Maria Găman"> <meta name="citation_author_institution" content="Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania"> <meta name="citation_author_institution" content="Clinic of Hematology, Filantropia City Hospital, Craiova 200143, Romania. gamanamelia@yahoo.com"> <meta name="citation_author" content="Camelia Cristina Diaconu"> <meta name="citation_author_institution" content="Department of Internal Medicine, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania"> <meta name="citation_author_institution" content="Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest 105402, Romania"> <meta name="citation_publication_date" content="2024 Jun 24"> <meta name="citation_volume" content="15"> <meta name="citation_issue" content="6"> <meta name="citation_firstpage" content="717"> <meta name="citation_doi" content="10.5306/wjco.v15.i6.717"> <meta name="citation_pmid" content="38946827"> <meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/"> <meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/"> <meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/pdf/WJCO-15-717.pdf"> <meta name="description" content="Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are ..."> <meta name="og:title" content="Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms"> <meta name="og:type" content="article"> <meta name="og:site_name" content="PubMed Central (PMC)"> <meta name="og:description" content="Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are ..."> <meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/"> <meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@ncbi"> </head> <body > <a class="usa-skipnav " href="#main-content"> Skip to main content </a> <section class="usa-banner " aria-label="Official website of the United States government" > <div class="usa-accordion"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="grid-col-auto"> <img aria-hidden="true" class="usa-banner__header-flag" src="/static/img/us_flag.svg" alt="" /> </div> <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true"> <p class="usa-banner__header-text"> An official website of the United States government </p> <span class="usa-banner__header-action">Here's how you know</span> </div> <button type="button" class="usa-accordion__button usa-banner__button " aria-expanded="false" aria-controls="gov-banner-default" data-testid="storybook-django-banner" > <span class="usa-banner__button-text">Here's how you know</span> </button> </div> </header> <div class="usa-banner__content usa-accordion__content" id="gov-banner-default" hidden> <div class="grid-row grid-gap-lg"> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-dot-gov.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Official websites use .gov</strong> <br /> A <strong>.gov</strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-https.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Secure .gov websites use HTTPS</strong> <br /> A <strong>lock</strong> ( <span class="icon-lock"> <svg xmlns="http://www.w3.org/2000/svg" width="52" height="64" viewBox="0 0 52 64" class="usa-banner__lock-image" role="graphics-symbol" aria-labelledby="banner-lock-description" focusable="false"> <title id="banner-lock-title">Lock</title> <desc id="banner-lock-description"> Locked padlock icon </desc> <path fill="#000000" fill-rule="evenodd" d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" /> </svg> </span>) or <strong>https://</strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class="usa-overlay"> </div> <header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header > <div class="ncbi-header"> <div class="ncbi-header__container"> <a class="ncbi-header__logo-container" href="/"> <img alt=" PMC home page " class="ncbi-header__logo-image" src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" /> </a>  <button type="button" class="usa-menu-btn ncbi-header__hamburger-button " aria-label="Show menu" data-testid="navMenuButton" > <svg aria-hidden="true" class="ncbi-hamburger-icon" fill="none" focusable="false" height="21" viewBox="0 0 31 21" width="31" xmlns="http://www.w3.org/2000/svg"> <path clip-rule="evenodd" d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z" fill="#F1F1F1" fill-rule="evenodd" /> </svg> </button>  <div class="ncbi-header__desktop-buttons">  <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button " aria-expanded="false" aria-controls="search-field-desktop-navigation" aria-label="Show search overlay" data-testid="toggleSearchPanelButton" data-toggle-search-panel-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#search" /> </svg> Search </button>  <div class="ncbi-header__login-dropdown"> <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button " aria-expanded="false" aria-controls="login-dropdown-menu" aria-label="Show login menu" data-testid="toggleLoginMenuDropdown" data-desktop-login-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#person" /> </svg> <span data-login-dropdown-text>Log in</span>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow> <use xlink:href="/static/img/sprite.svg#expand_less" /> </svg>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow> <use xlink:href="/static/img/sprite.svg#expand_more" /> </svg> </button>  <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu" id="login-dropdown-menu" data-desktop-login-menu-dropdown hidden> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> <li class="usa-nav__submenu-item"> <button type="button" class="usa-button usa-button--outline ncbi-header__login-dropdown-logout-button " data-testid="desktopLogoutButton" data-desktop-logout-button > Log out </button> </li> </ul> </div> </div> </div> </div>  <div class="ncbi-search-panel ncbi--show-only-at-desktop" data-testid="searchPanel" data-header-search-panel hidden> <div class="ncbi-search-panel__container"> <form action="https://www.ncbi.nlm.nih.gov/search/all/" aria-describedby="search-field-desktop-navigation-help-text" autocomplete="off" class="usa-search usa-search--big ncbi-search-panel__form" data-testid="form" method="GET" role="search"> <label class="usa-sr-only" data-testid="label" for="search-field-desktop-navigation"> Search… </label> <input class="usa-input" data-testid="textInput" id="search-field-desktop-navigation" name="term" placeholder="Search NCBI" type="search" value="" /> <button type="submit" class="usa-button " data-testid="button" > <span class="usa-search__submit-text"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="usa-nav"> <p class="usa-sr-only" id="primary-navigation-sr-only-title"> Primary site navigation </p>  <button type="button" class="usa-nav__close ncbi-nav__close-button " aria-label="Close navigation menu" data-testid="navCloseButton" > <img src="/static/img/usa-icons/close.svg" alt="Close" /> </button>  <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6" role="search"> <label class="usa-sr-only" for="search-field"> Search </label> <input class="usa-input" id="search-field-mobile-navigation" type="search" placeholder="Search NCBI" name="search" /> <button type="submit" class="usa-button " >  <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==" class="usa-search__submit-icon" alt="Search" /> </button> </form>   <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop" data-mobile-login-menu hidden> <p class="ncbi-nav__mobile-login-menu-status"> Logged in as: <strong class="ncbi-nav__mobile-login-menu-email" data-mobile-login-email-text></strong> </p> <ul class="usa-nav__primary usa-accordion"> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> </ul> </div> <button type="button" class="usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop " data-testid="mobileLoginButton" data-mobile-login-button > Log in </button> </nav> </header> <section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box"> <div class="pmc-nav-container"> <div class="pmc-header__bar"> <div class="pmc-header__logo"> <a href="/" title="Home" aria-label="PMC Home"></a> </div> <button type="button" class="usa-button usa-button--unstyled pmc-header__search__button" aria-label="Open search" data-ga-category="search" data-ga-action="PMC" data-ga-label="pmc_search_panel_mobile" > <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#search"></use> </svg> <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="pmc-header__search"> <form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search"> <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label> <span class="autoComplete_wrapper flex-1"> <input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="/search/autocomplete/"/> </span> <button class="usa-button" type="submit" formaction="https://www.ncbi.nlm.nih.gov/pmc/" data-ga-category="search" data-ga-action="PMC" data-ga-label="PMC_search_button" > <span class="usa-search__submit-text">Search in PMC</span> <img src="/static/img/usa-icons-bg/search--white.svg" class="usa-search__submit-icon" alt="Search" /> </button> </form> <ul class="pmc-header__search__menu"> <li> <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search"> Advanced Search </a> </li> <li> <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list"> Journal List </a> </li> <li> <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link" data-ga-label="user guide"> User Guide </a> </li> </ul> </div> </div> </section> <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11212607"> <div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary"> <div class="grid-row"> <div class="grid-col-fill display-flex"> <div class="display-flex"> <ul class="usa-list usa-list--unstyled usa-list--horizontal"> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open resources" data-extra-class="is-visible-resources" data-ga-category="resources_accordion" data-ga-action="click" data-ga-label="mobile_icon" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#more_vert"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <a href="https://doi.org/10.5306/wjco.v15.i6.717" class="usa-link display-flex" role="button" target="_blank" rel="noreferrer noopener" aria-label="View on publisher site" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#launch"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <a href="pdf/WJCO-15-717.pdf" class="usa-link display-flex" role="button" aria-label="Download PDF" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button class="usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_mobile" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11212607%2F%23open-collections-dialog" data-in-collections="false" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button role="button" class="usa-button usa-button--unstyled citation-dialog-trigger display-flex" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_mobile" data-all-citations-url="/resources/citations/11212607/" data-citation-style="nlm" data-download-format-link="/resources/citations/11212607/export/" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> </button> </li> <li class="pmc-permalink display-flex"> <button type="button" class="usa-button usa-button--unstyled display-flex" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </div> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open article navigation" data-extra-class="is-visible-in-page" data-ga-category="actions" data-ga-action="open" data-ga-label="article_nav_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#list"></use> </svg> </button> </div> </div> </div> <div class="grid-container desktop:padding-left-6"> <div id="article-container" class="grid-row grid-gap"> <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content"> <div class="grid-container padding-left-0 padding-right-0"> <div class="grid-row desktop:margin-left-neg-6"> <div class="grid-col-12"> <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.<br/> Learn more: <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a> | <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/"> PMC Copyright Notice </a> </div> </div> </div> <div class="grid-row pmc-wm desktop:margin-left-neg-6">  <main id="main-content" class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0" > <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-wjco.gif" alt="World Journal of Clinical Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to World Journal of Clinical Oncology" title="Link to World Journal of Clinical Oncology" shape="default" href="http://www.wjgnet.com/2218-4333/archive.htm" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div> <div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">World J Clin Oncol</button></div>. 2024 Jun 24;15(6):717–729. doi: <a href="https://doi.org/10.5306/wjco.v15.i6.717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.5306/wjco.v15.i6.717</a> </div> <nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu"> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22World%20J%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li> <li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22World%20J%20Clin%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22World%20J%20Clin%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li> <li role="presentation"><a href="?term=%22World%20J%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li> </ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs"> <hgroup><h1>Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms</h1></hgroup><div class="cg p"> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C4%83man%20MA%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mihnea-Alexandru Găman</span></a><div hidden="hidden" id="id1"> <h3><span class="name western">Mihnea-Alexandru Găman</span></h3> <div class="p"> <sup>1</sup>Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania</div> <div class="p"> <sup>2</sup>Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania</div> <div class="p"> <sup>3</sup>Department of Cellular and Molecular Pathology, Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest 030304, Romania</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C4%83man%20MA%22%5BAuthor%5D" class="usa-link"><span class="name western">Mihnea-Alexandru Găman</span></a> </div> </div> <sup>1,</sup><sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Srichawla%20BS%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Bahadar Singh Srichawla</span></a><div hidden="hidden" id="id2"> <h3><span class="name western">Bahadar Singh Srichawla</span></h3> <div class="p"> <sup>4</sup>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Srichawla%20BS%22%5BAuthor%5D" class="usa-link"><span class="name western">Bahadar Singh Srichawla</span></a> </div> </div> <sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20YF%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yong-Feng Chen</span></a><div hidden="hidden" id="id3"> <h3><span class="name western">Yong-Feng Chen</span></h3> <div class="p"> <sup>5</sup>Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20YF%22%5BAuthor%5D" class="usa-link"><span class="name western">Yong-Feng Chen</span></a> </div> </div> <sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roy%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Poulami Roy</span></a><div hidden="hidden" id="id4"> <h3><span class="name western">Poulami Roy</span></h3> <div class="p"> <sup>6</sup>Department of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roy%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Poulami Roy</span></a> </div> </div> <sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dhali%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Arkadeep Dhali</span></a><div hidden="hidden" id="id5"> <h3><span class="name western">Arkadeep Dhali</span></h3> <div class="p"> <sup>7</sup>Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dhali%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arkadeep Dhali</span></a> </div> </div> <sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nahian%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ahmed Nahian</span></a><div hidden="hidden" id="id6"> <h3><span class="name western">Ahmed Nahian</span></h3> <div class="p"> <sup>8</sup>Lecom at Seton Hill, Greensburg, PA 15601, United States</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nahian%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed Nahian</span></a> </div> </div> <sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Manan%20MR%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Muhammad Romail Manan</span></a><div hidden="hidden" id="id7"> <h3><span class="name western">Muhammad Romail Manan</span></h3> <div class="p"> <sup>9</sup>Faculty of Medicine, Services Hospital, Lahore 54000, Pakistan</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Manan%20MR%22%5BAuthor%5D" class="usa-link"><span class="name western">Muhammad Romail Manan</span></a> </div> </div> <sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kipkorir%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Vincent Kipkorir</span></a><div hidden="hidden" id="id8"> <h3><span class="name western">Vincent Kipkorir</span></h3> <div class="p"> <sup>10</sup>Department of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kipkorir%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vincent Kipkorir</span></a> </div> </div> <sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Suteja%20RC%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Richard Christian Suteja</span></a><div hidden="hidden" id="id9"> <h3><span class="name western">Richard Christian Suteja</span></h3> <div class="p"> <sup>11</sup>Faculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Suteja%20RC%22%5BAuthor%5D" class="usa-link"><span class="name western">Richard Christian Suteja</span></a> </div> </div> <sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Simhachalam%20Kutikuppala%20LV%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Lakshmi Venkata Simhachalam Kutikuppala</span></a><div hidden="hidden" id="id10"> <h3><span class="name western">Lakshmi Venkata Simhachalam Kutikuppala</span></h3> <div class="p"> <sup>12</sup>Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Simhachalam%20Kutikuppala%20LV%22%5BAuthor%5D" class="usa-link"><span class="name western">Lakshmi Venkata Simhachalam Kutikuppala</span></a> </div> </div> <sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C4%83man%20AM%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Amelia Maria Găman</span></a><div hidden="hidden" id="id11"> <h3><span class="name western">Amelia Maria Găman</span></h3> <div class="p"> <sup>13</sup>Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania</div> <div class="p"> <sup>14</sup>Clinic of Hematology, Filantropia City Hospital, Craiova 200143, Romania. gamanamelia@yahoo.com</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C4%83man%20AM%22%5BAuthor%5D" class="usa-link"><span class="name western">Amelia Maria Găman</span></a> </div> </div> <sup>13,</sup><sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diaconu%20CC%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Camelia Cristina Diaconu</span></a><div hidden="hidden" id="id12"> <h3><span class="name western">Camelia Cristina Diaconu</span></h3> <div class="p"> <sup>15</sup>Department of Internal Medicine, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania</div> <div class="p"> <sup>16</sup>Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest 105402, Romania</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diaconu%20CC%22%5BAuthor%5D" class="usa-link"><span class="name western">Camelia Cristina Diaconu</span></a> </div> </div> <sup>15,</sup><sup>16</sup> </div> <ul class="d-buttons inline-list"> <li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li> <li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li> <li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li> </ul> <div class="d-panels font-secondary-light"> <div id="aip_a" class="d-panel p" style="display: none"> <div class="p" id="aff1"> <sup>1</sup>Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania</div> <div id="aff2"> <sup>2</sup>Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania</div> <div id="aff3"> <sup>3</sup>Department of Cellular and Molecular Pathology, Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest 030304, Romania</div> <div id="aff4"> <sup>4</sup>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States</div> <div id="aff5"> <sup>5</sup>Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China</div> <div id="aff6"> <sup>6</sup>Department of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India</div> <div id="aff7"> <sup>7</sup>Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom</div> <div id="aff8"> <sup>8</sup>Lecom at Seton Hill, Greensburg, PA 15601, United States</div> <div id="aff9"> <sup>9</sup>Faculty of Medicine, Services Hospital, Lahore 54000, Pakistan</div> <div id="aff10"> <sup>10</sup>Department of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya</div> <div id="aff11"> <sup>11</sup>Faculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia</div> <div id="aff12"> <sup>12</sup>Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India</div> <div id="aff13"> <sup>13</sup>Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania</div> <div id="aff14"> <sup>14</sup>Clinic of Hematology, Filantropia City Hospital, Craiova 200143, Romania. gamanamelia@yahoo.com</div> <div id="aff15"> <sup>15</sup>Department of Internal Medicine, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania</div> <div id="aff16"> <sup>16</sup>Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest 105402, Romania</div> <div class="author-notes p"><div class="fn" id="fn1"> <sup>✉</sup><p class="display-inline">Author contributions: Găman MA contributed to the study conceptualization, data curation, funding acquisition, methodology, resources, validation, visualization, and software; Găman MA, Srichawla BS, Chen YF, Roy P, Dhali A, Nahian A, Manan MR, Kipkorir V, Suteja RC, and Simhachalam Kutikuppala LV contributed to the formal analysis, investigation, and writing of the original draft; Găman MA, Găman AM, and Diaconu CC contributed to the project administration and supervision; Găman MA, Srichawla BS, Găman AM, and Diaconu CC contributed to the writing, review, and editing.</p> <p>Supported by the Grant Funded by Competitiveness Operational Programme A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT (to Găman MA), No. 149/26.10.2016 (MySMIS2014+: 106774).</p> <p>Corresponding author: Amelia Maria Găman, Doctor, MD, PhD, Doctor, Professor, Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Petru Rareş No. 2, Craiova 200349, Romania. <span>gamanamelia@yahoo.com</span></p> </div></div> </div> <div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Mar 12; Revised 2024 May 5; Accepted 2024 May 28; Issue date 2024 Jun 24.</p></section></div></div> <div id="clp_a" class="d-panel p" style="display: none"> <div>©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</div> <p>This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</p> <div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div> </div> </div> <div>PMCID: PMC11212607 PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38946827/" class="usa-link">38946827</a> </div> </div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2> <p>Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.</p> <section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Polycythemia vera, Essential thrombocythemia, Myelofibrosis, Cardiovascular disease, Hypercholesterolemia, Hypertriglyceridemia, Obesity, Diabetes, Inflammation, Oxidative stress</p></section></section><hr class="headless"> <p> <strong>Core Tip:</strong> The topic of dyslipidemia in myeloproliferative neoplasms (MPNs) has only been superficially studied to date. Although it is well known that cardiovascular risk factors impact the management of MPNs and increase the risk of thrombosis which is the main cause of death in MPNs, most investigations have overlooked dyslipidemia as a significant contributor to thrombotic risk and to the risk of death in MPNs. Herein, we provide, to the best of our knowledge, the first overview of lipid abnormalities in MPNs.</p> <section id="sec1"><h2 class="pmc_sec_title">INTRODUCTION</h2> <p>Hematopoietic pluripotent stem cells (HPSCs) exhibit a remarkable capacity for self-renewal and undergo differentiation into myeloid or lymphoid lineages. This intricate hematopoietic process culminates in the emergence of various mature blood cells (BCs), which include red BCs (RBCs), lymphocytes, granulocytes, megakaryocytes, and macrophages. The orchestration of hematopoiesis is intricately governed by the complex interplay of the bone marrow microenvironment, growth factors, and transcriptional regulators[<a href="#B1" class="usa-link" aria-describedby="B1">1</a>].</p> <p>Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. This results in the manifestation of a heterogeneous group of disorders. The initial term “myeloproliferative disorders,” originally introduced by William Dameshek in 1951, has been formally standardized and rephrased as “myeloproliferative neoplasms” by the World Health Organization in 2016[<a href="#B2" class="usa-link" aria-describedby="B2">2</a>].</p> <p>Within the classification of MPNs, the updated document encompasses seven distinct subcategories: chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia-not otherwise specified and MPN, unclassifiable. Notably, it is imperative to highlight that mastocytosis no longer falls under the MPN category. This revised categorization represents a pivotal advance in the field, indicating a comprehensive and rigorous approach to classifying these complex disorders[<a href="#B2" class="usa-link" aria-describedby="B2">2</a>,<a href="#B3" class="usa-link" aria-describedby="B3">3</a>].</p> <p>PV is a chronic myeloproliferative neoplastic disorder characterized by the uncontrolled production of RBCs, resulting in an elevated mass of RBCs. This condition often leads to concurrent stimulation of myeloid and megakaryocytic lineages, leading to increased production of white BCs and platelets. Pathophysiology involves abnormal hematopoietic cell clones with increased sensitivity to growth factors. Signs and symptoms such as headache, dizziness, claudication, and thrombosis arise due to increased blood viscosity. Subjects diagnosed with PV exhibit driver mutations in the Janus kinase 2 (<em>JAK2</em>) gene. In > 95% of cases, the <em>JAK2V617F</em> mutation is detected in exon 14 of the aforementioned gene, and the remaining 3%-4% of affected individuals exhibit mutations in exon 12 of the <em>JAK2</em> gene[<a href="#B4" class="usa-link" aria-describedby="B4">4</a>,<a href="#B5" class="usa-link" aria-describedby="B5">5</a>]. Cytogenetic studies reveal abnormal karyotypes in about 34% of patients. PV affects all ethnic groups, with a higher incidence in men, and is usually diagnosed around 60-years-old[<a href="#B6" class="usa-link" aria-describedby="B6">6</a>]. In the United States, the overall incidence of PV between 2002 and 2016 was 1.57 (1.55-1.60) per 100000 person years, with fewer cases reported in Japan compared to the United States and Europe[<a href="#B6" class="usa-link" aria-describedby="B6">6</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a>].</p> <p>ET is another classical BCR-ABL1-negative MPN. It is characterized by excessive platelet production and megakaryocytic hyperplasia in the bone marrow. Initially identified in 1934 under the name “hemorrhagic thrombocythemia”, it was subsequently classified as MPN by Damesheck in 1951[<a href="#B8" class="usa-link" aria-describedby="B8">8</a>]. About 55% of patients with ET harbor the <em>JAK2V617F</em> point mutation[<a href="#B9" class="usa-link" aria-describedby="B9">9</a>,<a href="#B10" class="usa-link" aria-describedby="B10">10</a>]. ET is related to the development of vascular complications, for example, thrombosis and hemorrhage, which are associated with the presence of thrombocytosis, and there is a possibility of progression of the disease to secondary myelofibrosis (MF)[<a href="#B11" class="usa-link" aria-describedby="B11">11</a>,<a href="#B12" class="usa-link" aria-describedby="B12">12</a>]. ET is more prevalent among MPNs, affecting 1.0 to 2.5 individuals per 100000 yearly, with a higher incidence in females. The condition becomes more common with age, and most cases present between the ages of 50 and 60[<a href="#B13" class="usa-link" aria-describedby="B13">13</a>,<a href="#B14" class="usa-link" aria-describedby="B14">14</a>].</p> <p>PMF is characterized by the clonal overproduction of myeloid cells originating from HPSCs. Although not always present, PMF often involves mutations in the <em>JAK2</em>, calreticulin, or myeloproliferative leukemia genes. Additional features include the abnormal presence of collagen fibrosis in the bone marrow, the dysregulated expression of inflammatory cytokines, anemia, hepatosplenomegaly, extramedullary hematopoiesis, constitutional symptoms, cachexia, the risk of progression to acute leukemia, and reduced life expectancy. The incidence of MF in the European Union varies between 0.3 and 1.9 per 100000 people, with an average of 1.1 per 100000[<a href="#B15" class="usa-link" aria-describedby="B15">15</a>]. In the United States, the annual incidence of MF is 1.33 per 100000[<a href="#B16" class="usa-link" aria-describedby="B16">16</a>]. In high-income countries of the European Union, the prevalence of MF ranges from 0.5 to 9 per 100000 per year[<a href="#B15" class="usa-link" aria-describedby="B15">15</a>]. The global prevalence of MF is approximately 1 per 100000 people[<a href="#B16" class="usa-link" aria-describedby="B16">16</a>].</p></section><section id="sec2"><h2 class="pmc_sec_title">BRIEF OVERVIEW OF CARDIOVASCULAR RISK FACTORS IN MPNs</h2> <p>Subjects suffering from MPNs exhibit a high burden of cardiovascular risk factors (CVRFs), thrombotic events often being the cause of death in this patient population[<a href="#B17" class="usa-link" aria-describedby="B17">17</a>-<a href="#B19" class="usa-link" aria-describedby="B19">19</a>]. In a recent publication by Seguro <em>et al</em>[<a href="#B20" class="usa-link" aria-describedby="B20">20</a>], the authors conducted a retrospective analysis of hemorrhagic and thrombotic events in a cohort of 334 Brazilian patients with Philadelphia-negative chronic MPNs. The study identified risk factors associated with thrombosis in these patients. The authors of the study used the revised International Prognostic Score in ET to classify patients into four risk categories using four variables: CVRFs, history of thrombosis, age > 60 years, and presence of the <em>JAK2V617F</em> mutation. However, CVRFs were not taken into account in the risk assessment of PV and MF in this study. Currently, thrombotic risk in PV is assessed using traditional classification, which classifies individuals as low- or high-risk based on their age (< or > 60 years) and history of thrombosis[<a href="#B20" class="usa-link" aria-describedby="B20">20</a>]. In the case of MF, there is currently no validated score to assess thrombotic risk. However, current evidence suggests that one or more CVRF, such as hypertension, diabetes, cigarette smoking, dyslipidemia, or obesity, may increase the risk of thrombosis in MPNs[<a href="#B21" class="usa-link" aria-describedby="B21">21</a>]. The previously agreed thrombotic risk classification models for PV and ET introduced an intermediate risk category in addition to the traditional high and low risk categories. This intermediate-risk category included patients under the age of 60 years of age with no history of thrombosis, but with the presence of CVRFs. However, this thrombotic risk classification model is not widely used in clinical practice[<a href="#B22" class="usa-link" aria-describedby="B22">22</a>].</p> <p>Cerquozzi <em>et al</em>[<a href="#B23" class="usa-link" aria-describedby="B23">23</a>] conducted a study to investigate the association between CVRF and the onset of arterial or venous thrombotic complications in patients with MPNs at or after diagnosis[<a href="#B23" class="usa-link" aria-describedby="B23">23</a>]. The findings of their investigation revealed that dyslipidemia, age < 60 years, diabetes, normal karyotype, and hypertension were associated with the development of arterial events. On the other hand, female sex, a history of major hemorrhage, palpable splenomegaly, and age < 60 years were associated with thrombosis in the venous territories[<a href="#B23" class="usa-link" aria-describedby="B23">23</a>].</p> <p>In a recent report by Barbui <em>et al</em>[<a href="#B24" class="usa-link" aria-describedby="B24">24</a>], hypertension in low-risk patients with PV was emphasized to increase the risk of arterial thrombosis[<a href="#B24" class="usa-link" aria-describedby="B24">24</a>]. Currently, for patients with PV or ET who are > 60 years of age and have one or more CVRF, cytoreductive therapy is not recommended. In the revised 2018 management recommendations for classical MPNs negative for BCR-ABL1 issued by European LeukemiaNet, Barbui <em>et al</em>[<a href="#B25" class="usa-link" aria-describedby="B25">25</a>] argued for the consideration of general risk factors for thrombosis, such as smoking consumption, diabetes mellitus, hypertension and hypercholesterolemia, in the management of MPNs[<a href="#B25" class="usa-link" aria-describedby="B25">25</a>].</p> <p>Accurso <em>et al</em>[<a href="#B26" class="usa-link" aria-describedby="B26">26</a>] analyzed a cohort of 603 MPN patients who were followed from January 1997 to December 2019 to assess the frequency of CVRF in this population of patients[<a href="#B26" class="usa-link" aria-describedby="B26">26</a>]. They investigated the prevalence of smoking, hypertension, diabetes, dyslipidemia, and obesity in different disease subgroups, including 138 cases of overt PMF or post-ET/post-PV MF, 48 cases of prefibrotic PMF, 169 cases of PV, and 249 cases of ET. They also differentiated patients with a single CVRF from those with multiple CVRFs. The overall prevalence of CVRFs in the MPN cohort was 75.95%, with 40.63% of patients having only one CVRF and 35.32% having multiple risk factors. The median age of CVRF patients was 67.57 years, while those without CVRF had a median age of 53.98 years (<em>P</em> < 0.001). The high frequency of CVRF in MPNs raises important questions regarding prognosis and therapeutic decisions[<a href="#B26" class="usa-link" aria-describedby="B26">26</a>]. However, conclusive data on the impact of CVRFs on thrombotic risk in Philadelphia-negative chronic MPNs are lacking. Prospective studies are needed to determine the risk of thrombotic inflammation in patients with MPNs, both with and without CVRF. If it is demonstrated that CVRFs significantly increase thrombotic risk in MPNs, cytoreductive therapy may be warranted for these individuals. More research is needed to establish the exact relationship between cardiovascular and thrombotic risk in MPNs and inform appropriate therapeutic strategies.</p></section><section id="sec3"><h2 class="pmc_sec_title">EPIDEMIOLOGY OF DYSLIPIDEMIA IN MPNs AND ITS IMPACT ON THROMBOSIS AND SURVIVAL</h2> <p>Dyslipidemia and metabolic syndrome (MetS) remain some of the most common CVRFs in the general population. Dyslipidemia has traditionally been defined as alterations in serum cholesterol concentrations: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and/or high-density lipoprotein cholesterol (HDL-C) and/or triglycerides (TGs)[<a href="#B27" class="usa-link" aria-describedby="B27">27</a>]. However, recent evidence suggests that secondary lipid biomarkers, for example, lipoprotein(a), apolipoproteins, lipid subclasses, and/or subfractions, may provide additional information in terms of cardiovascular risk assessment[<a href="#B27" class="usa-link" aria-describedby="B27">27</a>-<a href="#B29" class="usa-link" aria-describedby="B29">29</a>]. Furthermore, the MetS which comprises the association in various levels of insulin resistance, hypertension, atherogenic dyslipidemia, and central obesity is also associated with the appearance of cardiovascular events[<a href="#B30" class="usa-link" aria-describedby="B30">30</a>].</p> <p>The interplay of dyslipidemia, MetS, and obesity has been extensively studied not only in the field of cardiology but also by oncology researchers. Metabolic dysfunction has been particularly associated with the development and outcome of a myriad of solid cancers, as well as hematologic malignancies such as lymphoma, multiple myeloma, acute and chronic leukemias, as well as myelodysplastic syndromes and MPNs[<a href="#B31" class="usa-link" aria-describedby="B31">31</a>-<a href="#B33" class="usa-link" aria-describedby="B33">33</a>]. Furthermore, low concentrations of apolipoprotein A1 (hazard ratio [HR] = 1.59, 95% confidence interval [CI]: 1.22-2.08; <em>P</em> < 0.001] and/or high-density lipoprotein cholesterol (HR = 1.66, 95%CI: 1.22-2.26; <em>P</em> < 0.001) have been associated with an elevated risk of MPNs even after multiple comparisons were considered[<a href="#B33" class="usa-link" aria-describedby="B33">33</a>].</p> <p>A recent cohort study that evaluated 1537 individuals diagnosed with <em>JAK2V617F</em>-positive MPNs reported that dyslipidemia is the second most common CVRF after hypertension in these disorders. Overall, 14.1% of the cases analyzed suffered from hyperlipidemia, which particularly affected PV (16.1%) and PMF (16%) rather than ET subjects (12%). Furthermore, MPN individuals who developed thrombotic events were more frequently described as dyslipidemia compared to those who were thrombosis-free (62.1% <em>vs</em> 37.9%; <em>P</em> < 0.0001). However, this investigation confirmed CVRFs as predictive factors of thrombotic complications in MPNs[<a href="#B34" class="usa-link" aria-describedby="B34">34</a>].</p> <p>Similarly, Guglielmelli <em>et al</em>[<a href="#B35" class="usa-link" aria-describedby="B35">35</a>] highlighted that, in their cohort of 382 subjects with prefibrotic PMF, dyslipidemia (12%) was the third most common CVRF after hypertension (27%) and smoking (14%)[<a href="#B35" class="usa-link" aria-describedby="B35">35</a>]. Furthermore, dyslipidemia was the CVRF most frequently discovered (16%) after hypertension (42.2%) and diabetes (18.6%) in a cohort of 668 patients with PMF and MF post-PV/post-ET. Furthermore, the authors revealed a negative association between survival and the presence of dyslipidemia in MF (HR = 4.65, 95%CI: 3.11-6.95; <em>P</em> < 0.001) in the univariate analysis. However, multivariate Cox proportional hazard models failed to demonstrate their impact on survival[<a href="#B36" class="usa-link" aria-describedby="B36">36</a>]. Accurso <em>et al</em>[<a href="#B37" class="usa-link" aria-describedby="B37">37</a>] also confirmed that dyslipidemia is second among CVRF in people with PV (28.75%) and ET (24.89%) after hypertension based on data derived from a cohort of 403 MPN patients and that CVRFs are associated with an elevated risk of thrombotic events in MPNs[<a href="#B37" class="usa-link" aria-describedby="B37">37</a>]. Furthermore, Stein <em>et al</em>[<a href="#B38" class="usa-link" aria-describedby="B38">38</a>] highlighted that dyslipidemia was notably associated with a history of thrombotic events (odds ratio [OR] = 2.31, 95%CI: 1.00-5.34; <em>P</em> = 0.05) in MPN subjects who harbor the <em>JAK2V617F</em> mutation[<a href="#B38" class="usa-link" aria-describedby="B38">38</a>]. Another assessment indicated that CVRF (obesity, dyslipidemia, diabetes, hypertension, use of cigarettes) are predictors of thrombotic complications after MPN diagnosis (HR = 4.22, 95%CI: 2.00-8.92; <em>P</em> < 0.001)[<a href="#B39" class="usa-link" aria-describedby="B39">39</a>].</p> <p>Horvat <em>et al</em>[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>] analyzed a cohort of 258 MPN individuals who developed arterial and/or venous thrombosis and revealed that dyslipidemia was associated with the development of the aforementioned vascular events (OR = 3.5, 95%CI: 1.8-6.8; <em>P</em> < 0.001). However, dyslipidemia was more likely to be associated with the development of arterial (OR = 4.1, 95%CI: 2.0-8.3; <em>P</em> < 0.001) rather than venous (OR = 1.5, 95%CI: 0.5-4.5; <em>P</em> = 0.330) thrombotic complications[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>]. When researchers analyzed thrombotic events by MPN subtype and site of thrombosis, dyslipidemia was only related to arterial but not venous thrombosis in ET (OR = 4.5, 95%CI: 1.6-12.6; <em>P</em> = 0.006) and PMF (OR = 6.1, 95%CI: 1.1-33.6; <em>P</em> = 0.046)[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>]. Furthermore, a Japanese study indicated that elevated serum TG concentrations are positively associated with thrombotic events in ET (HR = 3.530, 95%CI: 1.630-7.643; <em>P</em> < 0.001), whereas elevated serum LDL-C concentrations were marginally associated with vascular events in ET (HR = 2.191, 95%CI: 0.966-4.971; <em>P</em> = 0.061) in the univariate model. Furthermore, elevated serum TG concentrations were the only CVRF associated with thrombosis in ET (HR = 3.364, 95%CI: 1.541-7.346; <em>P</em> = 0.002) in the multivariate model, while the role of elevated serum LDL-C concentrations warrants further investigation (HR = 2.046, 95%CI: 0.895-4.676; <em>P</em> = 0.09). More specifically, serum TG concentrations ≥ 106.19 mg/dL were associated with decreased thrombosis-free survival in patients with ET patients (HR = 2.592; <em>P</em> = 0.026)[<a href="#B41" class="usa-link" aria-describedby="B41">41</a>].</p> <p>Košťál <em>et al</em>[<a href="#B42" class="usa-link" aria-describedby="B42">42</a>] analyzed data from the Czech MPN registry to identify risk factors for stroke and/or transient ischemic attack in anagrelide-treated MPNs, revealing that increased serum TC (34.6% <em>vs</em> 28.5%) and TG (30.6% <em>vs</em> 19.4%) concentrations were more frequent in MPN patients who developed cerebrovascular events <em>vs</em> those who did not. However, in the univariate and multivariate analysis, respectively, only hypertriglyceridemia emerged as a notable risk factor for cerebrovascular events (HR = 1.734, 95%CI: 1.162-2.586; <em>P</em> = 0.008) whereas hypercholesterolemia did not impact the onset of these complications. Furthermore, hypertriglyceridemia and not hypercholesterolemia remained a significant risk factor for cerebrovascular events even in MPN individuals who did not receive cytoreductive treatment (OR = 2.265, 95%CI: 1.188-4.318; <em>P</em> = 0.015)[<a href="#B42" class="usa-link" aria-describedby="B42">42</a>].</p> <p>It is well established that patients with MPNs experience an elevated occurrence of vascular complications. In the largest epidemiological study on PV, CVRFs such as nonhemorrhagic stroke, congestive heart failure, coronary heart disease, and pulmonary embolism contributed to 41% of all deaths[<a href="#B43" class="usa-link" aria-describedby="B43">43</a>]. Nonfatal thrombosis occurred at a rate of 3.8 events per year per 100 persons[<a href="#B44" class="usa-link" aria-describedby="B44">44</a>]. Similarly, in patients with ET, the rate of thrombosis ranges from 2% to 4% by patients years. One of these thrombotic complications of particular interest due to its severity is splanchnic vein thrombosis. Other microcirculatory thrombosis can also occur that results in vascular headaches, dizziness, visual impairment, distal paresthesia, and erythromelalgia[<a href="#B43" class="usa-link" aria-describedby="B43">43</a>].</p> <p>Multivariate analyses of CVRFs such as dyslipidemia, hypertension, diabetes, and smoking, which investigated the impact on the occurrence of thrombosis in MPNs, have produced conflicting results. Some authors have reported that these risk factors do not influence vascular complications in MPNs, while others propose that the existence of these risks may elevate a low-risk patient to high-risk ED. In the recent International Prognostic Score of ET thrombosis score, the CVRFs mentioned above were independent variables influencing the rate of thrombosis[<a href="#B43" class="usa-link" aria-describedby="B43">43</a>,<a href="#B44" class="usa-link" aria-describedby="B44">44</a>]. However, data from a Japanese ET registry that included 1232 subjects of whom 17.6% exhibited elevated LDL-C and 8.4% elevated TG concentrations, respectively, suggests that dyslipidemia is not a predictor of survival in ET, however, hypertriglyceridemia significantly predicted thrombosis-free survival (HR = 3.018, 95%CI: 1.644-5.540; <em>P</em> < 0.001). Elevated LDL-C marginally predicted (HR = 1.722, 95%CI: 0.979-3.029; <em>P</em> = 0.059) thrombosis-free survival, which warrants investigating this potential thrombotic risk factor in future assessments[<a href="#B45" class="usa-link" aria-describedby="B45">45</a>]. CVRFs also appear to be associated with recurrent thrombosis in ET (OR = 3.148, 95%CI: 1.414-7.010; <em>P</em> = 0.005); however, the prevalence of dyslipidemia was similar between patients with/without recurrent thrombotic events[<a href="#B46" class="usa-link" aria-describedby="B46">46</a>].</p> <p>Interestingly, in a multicentric Italian cohort that recruited 816 subjects with PV of whom a number of 44 individuals eventually progressed to secondary MF (post-VV), overweight and/or obese PV patients had reduced chances of developing post-VV MF (HR = 0.38, 95%CI = 0.15-0.94; <em>P</em> = 0.04) and, in addition, experienced elevated survival rates (HR = 0.42, 95%CI: 0.18-0.97; <em>P</em> = 0.04)[<a href="#B47" class="usa-link" aria-describedby="B47">47</a>]. However, it seems that MPN patients who also suffer from obesity show an increased burden of symptoms and a reduced quality of life compared to normal weight MPN subjects[<a href="#B48" class="usa-link" aria-describedby="B48">48</a>]. This indicates that the perception of people living with MPNs about their quality of life and total symptom burden is also modeled by their cardiovascular comorbidities and increased symptom scores or reduced quality of life scores are not always indicative of disease progression[<a href="#B48" class="usa-link" aria-describedby="B48">48</a>,<a href="#B17" class="usa-link" aria-describedby="B17">17</a>]. However, Aswad <em>et al</em>[<a href="#B49" class="usa-link" aria-describedby="B49">49</a>] reported that obesity does not impact the overall rate of thrombotic events or recurrent thrombosis, nor the rates of arterial/vein thrombosis or microvascular disturbances in MPNs and that hereditary thrombophilia is more likely to contribute to the development of thrombotic complications (OR = 2.26; <em>P</em> = 0.007) and in particular arterial thrombosis (OR = 2.04; <em>P</em> = 0.046) <em>vs</em> CVRF[<a href="#B49" class="usa-link" aria-describedby="B49">49</a>].</p> <p>Table <a href="#T1" class="usa-link">1</a> summarizes the most relevant findings regarding the interplay between dyslipidemia and/other metabolic disturbances and thrombosis in MPNs.</p> <section class="tw xbox font-sm" id="T1"><h3 class="obj_head">Table 1.</h3> <div class="caption p"><p>Relevant results on the interaction between dyslipidemia and other metabolic disturbances and thrombosis or other factors in myeloproliferative neoplasm</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <thead><tr> <td rowspan="1" colspan="1"> <strong>Ref.</strong> <hr> </td> <td rowspan="1" colspan="1"> <strong>Study sample</strong> <hr> </td> <td rowspan="1" colspan="1"> <strong>MPN subtypes</strong> <hr> </td> <td rowspan="1" colspan="1"> <strong>Main findings</strong> <hr> </td> </tr></thead> <tbody> <tr> <td rowspan="1" colspan="1">Pedersen <em>et al</em>[<a href="#B33" class="usa-link" aria-describedby="B33">33</a>]</td> <td rowspan="1" colspan="1">116728</td> <td rowspan="1" colspan="1">Not specified</td> <td rowspan="1" colspan="1">↓ Apolipoprotein A1 (HR = 1.59, 95%CI: 1.22-2.08; <em>P</em> < 0.001) = ↑ risk of MPNs</td> </tr> <tr> <td rowspan="1" colspan="1">Pedersen <em>et al</em>[<a href="#B33" class="usa-link" aria-describedby="B33">33</a>]</td> <td rowspan="1" colspan="1">116728</td> <td rowspan="1" colspan="1">Not specified</td> <td rowspan="1" colspan="1">↓ HDL-C (HR = 1.66, 95%CI: 1.22-2.26; <em>P</em> < 0.001) = ↑ risk of MPNs</td> </tr> <tr> <td rowspan="1" colspan="1">Zhang <em>et al</em>[<a href="#B34" class="usa-link" aria-describedby="B34">34</a>]</td> <td rowspan="1" colspan="1">1537</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">↑ Rates of dyslipidemia in MPNs individuals with thrombotic events <em>vs</em> thrombosis-free (62.1% <em>vs</em> 37.9%; <em>P</em> < 0.0001)</td> </tr> <tr> <td rowspan="1" colspan="1">García-Fortes<br><em>et al</em>[<a href="#B36" class="usa-link" aria-describedby="B36">36</a>]</td> <td rowspan="1" colspan="1">668</td> <td rowspan="1" colspan="1">PMF, post-PV MF, post-ET MF</td> <td rowspan="1" colspan="1">Negative association of survival and dyslipidemia in MF (HR = 4.65, 95%CI: 3.11-6.95; <em>P</em> < 0.001)</td> </tr> <tr> <td rowspan="1" colspan="1">Stein <em>et al</em>[<a href="#B38" class="usa-link" aria-describedby="B38">38</a>]</td> <td rowspan="1" colspan="1">164</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">Association of dyslipidemia and history of thrombotic events (OR = 2.31, 95%CI: 1.00-5.34; <em>P</em> = 0.05) in <em>JAK2V617F-</em>positive MPNs</td> </tr> <tr> <td rowspan="1" colspan="1">Gu <em>et al</em>[<a href="#B39" class="usa-link" aria-describedby="B39">39</a>]</td> <td rowspan="1" colspan="1">567</td> <td rowspan="1" colspan="1">PV</td> <td rowspan="1" colspan="1">CVRFs (including dyslipidemia) = predictors of thrombosis after MPN diagnosis (HR = 4.22, 95%CI: 2.00-8.92; <em>P</em> < 0.001)</td> </tr> <tr> <td rowspan="1" colspan="1">Horvat <em>et al</em>[<a href="#B40" class="usa-link" aria-describedby="B40">40</a>]</td> <td rowspan="1" colspan="1">258</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">Association between dyslipidemia and vascular events (OR = 3.5, 95%CI: 1.8-6.8; <em>P</em> < 0.001), arterial thrombosis (OR = 4.1, 95%CI: 2.0-8.3; <em>P</em> < 0.001), venous thrombosis (OR = 1.5, 95%CI: 0.5-4.5; <em>P</em> = 0.330), arterial thrombosis in ET (OR = 4.5, 95%CI: 1.6-12.6; <em>P</em> = 0.006), and PMF (OR = 6.1, 95%CI: 1.1-33.6; <em>P</em> = 0.046)</td> </tr> <tr> <td rowspan="1" colspan="1">Furuya <em>et al</em>[<a href="#B41" class="usa-link" aria-describedby="B41">41</a>]</td> <td rowspan="1" colspan="1">580</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">↑ TG positively associated with thrombotic events in ET (HR = 3.530, 95%CI: 1.630-7.643; <em>P</em> < 0.001)</td> </tr> <tr> <td rowspan="1" colspan="1">Furuya <em>et al</em>[<a href="#B41" class="usa-link" aria-describedby="B41">41</a>]</td> <td rowspan="1" colspan="1">580</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">LDL-C concentrations marginally associated with vascular events in ET (HR = 2.191, 95%CI: 0.966-4.971; <em>P</em> = 0.061)</td> </tr> <tr> <td rowspan="1" colspan="1">Furuya <em>et al</em>[<a href="#B41" class="usa-link" aria-describedby="B41">41</a>]</td> <td rowspan="1" colspan="1">580</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">↑ TG = only CVRF associated with thrombosis in ET (HR = 3.364, 95%CI: 1.541-7.346; <em>P</em> = 0.002)</td> </tr> <tr> <td rowspan="1" colspan="1">Furuya <em>et al</em>[<a href="#B41" class="usa-link" aria-describedby="B41">41</a>]</td> <td rowspan="1" colspan="1">580</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">TG ≥ 106.19 mg/dL = ↓ thrombosis-free survival in ET (HR = 2.592; P = 0.026)</td> </tr> <tr> <td rowspan="1" colspan="1">Košťál <em>et al</em>[<a href="#B42" class="usa-link" aria-describedby="B42">42</a>]</td> <td rowspan="1" colspan="1">1142</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">Hypertriglyceridemia not hypercholesterolemia = RF for cerebrovascular events (HR = 1.734, 95%CI: 1.162-2.586; <em>P</em> = 0.008)</td> </tr> <tr> <td rowspan="1" colspan="1">Košťál <em>et al</em>[<a href="#B42" class="usa-link" aria-describedby="B42">42</a>]</td> <td rowspan="1" colspan="1">1142</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">Hypertriglyceridemia and not hypercholesterolemia = RF for cerebrovascular events in MPNs without cytoreductive treatment (OR = 2.265, 95%CI: 1.188-4.318; <em>P</em> = 0.015)</td> </tr> <tr> <td rowspan="1" colspan="1">Hashimoto <em>et al</em>[<a href="#B45" class="usa-link" aria-describedby="B45">45</a>]</td> <td rowspan="1" colspan="1">1152</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">Hypertriglyceridemia predicts thrombosis-free survival (HR = 3.018, 95%CI: 1.644-5.540; <em>P</em> < 0.001)</td> </tr> <tr> <td rowspan="1" colspan="1">Hashimoto <em>et al</em>[<a href="#B45" class="usa-link" aria-describedby="B45">45</a>]</td> <td rowspan="1" colspan="1">1152</td> <td rowspan="1" colspan="1">ET</td> <td rowspan="1" colspan="1">↑ LDL-C marginally predicts thrombosis-free survival (HR = 1.722, 95%CI: 0.979-3.029; <em>P</em> = 0.059)</td> </tr> <tr> <td rowspan="1" colspan="1">Benevolo <em>et al</em>[<a href="#B47" class="usa-link" aria-describedby="B47">47</a>]</td> <td rowspan="1" colspan="1">816</td> <td rowspan="1" colspan="1">PV</td> <td rowspan="1" colspan="1">overweight/obese PV = ↓ post-PV MF rates (HR = 0.38, 95%CI = 0.15-0.94; <em>P</em> = 0.04)</td> </tr> <tr> <td rowspan="1" colspan="1">Benevolo <em>et al</em>[<a href="#B47" class="usa-link" aria-describedby="B47">47</a>]</td> <td rowspan="1" colspan="1">816</td> <td rowspan="1" colspan="1">PV</td> <td rowspan="1" colspan="1">overweight/obese PV = ↑ survival rates (HR = 0.42, 95%CI: 0.18-0.97; <em>P</em> = 0.04)</td> </tr> <tr> <td rowspan="1" colspan="1">Christensen <em>et al</em>[<a href="#B48" class="usa-link" aria-describedby="B48">48</a>]</td> <td rowspan="1" colspan="1">3114</td> <td rowspan="1" colspan="1">PV, ET, PMF</td> <td rowspan="1" colspan="1">obesity + MPNs = ↑ symptom burden & ↓ QoL <em>vs</em> normal-weight MPNs</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"><div class="fn" id="fn2"><p>CI: Confidence interval; CVRFs: Cardiovascular risk factors; ET: Essential thrombocythemia; HDL-C: High-density lipoprotein cholesterol; HR: Hazard ratio; MF: Myelofibrosis; MPNs: Myeloproliferative neoplasms; OR: Odds ratio; PMF: Primary myelofibrosis; PV: Polycythemia vera; QoL: Quality of life; RF: Risk factor; ↑ increased/elevated; ↓: Reduced/decreased.</p></div></div></section></section><section id="sec4"><h2 class="pmc_sec_title">MANAGEMENT OF DYSLIPIDEMIA AND METABOLIC SYNDROME IN MPNs AND IMPACT OF MPN THERAPY ON THE LIPID PROFILE</h2> <p>Patients with MPNs often have dyslipidemia and MetS, making their management a clinical challenge that requires a comprehensive and integrated approach. Dyslipidemia, characterized by an abnormal lipid profile, typically involves an increase in TC, LDL-C, and TG levels, along with a decrease in HDL-C levels, respectively. Dyslipidemia can contribute to the development of atherosclerosis and increase the risk of cardiovascular disease, and in patients with MPNs, it can trigger the onset of acute coronary syndromes[<a href="#B50" class="usa-link" aria-describedby="B50">50</a>,<a href="#B51" class="usa-link" aria-describedby="B51">51</a>].</p> <p>In patients without MPNs, the treatment of dyslipidemia depends on lifestyle modifications, including diet adjustments, increased physical activity, and weight reduction. Currently, pharmacotherapy, primarily with statins, that is β-Hydroxy β-methylglutaryl-CoA reductase inhibitors, is used when lifestyle modifications are not sufficient. For most patients, the goal is to lower LDL-C levels to less than 100 mg/dL, while those at very high cardiovascular risk may need to target an LDL-C level of less than 70 mg/dL[<a href="#B52" class="usa-link" aria-describedby="B52">52</a>]. MetS is a cluster of metabolic conditions: elevated blood pressure, central obesity, elevated serum TG, elevated fasting blood glucose, and low HDL-C levels. Each component independently increases the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality[<a href="#B53" class="usa-link" aria-describedby="B53">53</a>]. Treatment of MetS involves primarily targeting its components through lifestyle modifications and pharmacotherapy, as required.</p> <p>The American Diabetes Association and the American Heart Association have established specific goals for metabolic control in patients with MetS. Targets include blood pressure less than 130/80 mmHg, fasting blood glucose less than 100 mg/dL, and hemoglobin levels A1C below 7.0%. Furthermore, the primary objective of treating dyslipidemia as part of MetS is to reduce LDL-C; however, if TG is 200 mg/dL or greater, a secondary goal is to decrease non-HDL-C by 30% to 50% of the baseline of the patient[<a href="#B54" class="usa-link" aria-describedby="B54">54</a>].</p> <p>In the context of patients with MPNs, these metabolic disorders pose unique challenges. <em>JAK2</em> gene mutations, a common feature in MPNs, can exacerbate metabolic dysregulation. These mutations are known to activate the JAK/signal transducer and activator of transcription signaling pathway, leading to the proliferation of hematopoietic cells. JAK2 is an essential component of the insulin receptor signaling pathway; upon binding of insulin to its receptor, JAK2 phosphorylates the insulin receptor, leading to downstream signaling events that facilitate glucose uptake[<a href="#B55" class="usa-link" aria-describedby="B55">55</a>]. Some studies have demonstrated that carriers of <em>JAK2</em> gene mutations show increased insulin, hypoglycemia, and adipose tissue atrophy, reinforcing the link between this mutation and metabolic disorders[<a href="#B56" class="usa-link" aria-describedby="B56">56</a>]. Currently, there is growing evidence that <em>JAK2</em> gene mutations can lead to altered lipid metabolism due to increased metabolic demand[<a href="#B57" class="usa-link" aria-describedby="B57">57</a>,<a href="#B58" class="usa-link" aria-describedby="B58">58</a>].</p> <p>Furthermore, MPNs are associated with a pro-inflammatory state, which could affect insulin sensitivity and lipid metabolism through key homeostatic factors such as adiponectin, which warrants complete metabolic control[<a href="#B59" class="usa-link" aria-describedby="B59">59</a>]. Chronic inflammation is believed to contribute to the development of MetS through various mechanisms, including dysregulated adipocytokine production, increased insulin resistance, and direct effects on lipid metabolism[<a href="#B60" class="usa-link" aria-describedby="B60">60</a>,<a href="#B61" class="usa-link" aria-describedby="B61">61</a>].</p> <p>MPN-directed therapies can also influence the metabolic profile of these patients. Ruxolitinib, a JAK1/2 inhibitor, is commonly used in the treatment of MPNs. This drug has been associated with weight gain and metabolic changes. Weight gain associated with ruxolitinib is believed to occur due to blocking leptin signaling in the brain leading to increased fat accumulation[<a href="#B62" class="usa-link" aria-describedby="B62">62</a>]. Furthermore, Mesa <em>et al</em>[<a href="#B63" class="usa-link" aria-describedby="B63">63</a>] detected elevated concentrations of TC and LDL-C in patients treated with ruxolitinib compared to pretreatment levels of TC/LDL-C in the same patient cohort[<a href="#B63" class="usa-link" aria-describedby="B63">63</a>]. Ruxolitinib has also been shown to increase systolic blood pressure after 72 wk of administration (<em>P</em> = 0.03)[<a href="#B64" class="usa-link" aria-describedby="B64">64</a>]. This underscores the need for routine metabolic monitoring and personalized therapeutic strategies in patients with MPNs in such therapies. The use of statins is beneficial in patients with MPNs. In a large population-based cohort study involving 876 patients with ET, Podoltsev <em>et al</em>[<a href="#B65" class="usa-link" aria-describedby="B65">65</a>] demonstrated improved patient survival using statin therapy[<a href="#B65" class="usa-link" aria-describedby="B65">65</a>]. Furthermore, a nationwide Danish case-control study demonstrated lower odds of being diagnosed with MPNs among statin users, alluding to the possible anti-neoplastic mechanisms of statin drugs[<a href="#B66" class="usa-link" aria-describedby="B66">66</a>]. The intricate interplay between MPNs, dyslipidemia, and MetS underscores the need for a comprehensive, multipronged approach to patient management. As our understanding of the biological connections between these conditions expands, we can expect to refine our therapeutic strategies further, ultimately improving patient outcomes.</p> <p>Although the main objective of MPN treatment is to control the overproduction of one or more types of BCs, emerging research has shown that MPN treatments can have unintended impacts on serum lipid concentrations of patients, potentially leading to dyslipidemia and MetS[<a href="#B67" class="usa-link" aria-describedby="B67">67</a>]. Dyslipidemia, a condition characterized by an abnormal amount of lipids in the blood, and MetS, a group of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal TC or TG levels, have been increasingly reported as side effects of various MPN treatments. These adverse effects can significantly affect the quality of life of patients, and if left untreated, they can contribute to the development of cardiovascular disease, a leading cause of death among patients with MPNs[<a href="#B68" class="usa-link" aria-describedby="B68">68</a>]. An investigation led by Sung <em>et al</em>[<a href="#B69" class="usa-link" aria-describedby="B69">69</a>] reported that patients treated with ruxolitinib exhibited increased levels of LDL-C and decreased levels of HDL-C, a lipid profile commonly associated with an increased risk of atherosclerotic cardiovascular disease[<a href="#B69" class="usa-link" aria-describedby="B69">69</a>]. Interferon-alpha, another treatment prescribed for MPNs, has also been shown to induce changes in lipid profiles. Sun <em>et al</em>[<a href="#B70" class="usa-link" aria-describedby="B70">70</a>] observed that treatment with pegylated interferon-alpha resulted in lower HDL-C levels in patients with PV, supporting the hypothesis that interferon-alpha may lead to dyslipidemia and therefore increase cardiovascular risk in MPN patients[<a href="#B70" class="usa-link" aria-describedby="B70">70</a>].</p> <p>It is important to note that MPN patients are already at increased risk of thrombosis due to the nature of the disease itself, and the addition of dyslipidemia and MetS can exacerbate this risk. The interplay between MPN treatment, lipid metabolism, and cardiovascular risk is complex and multifaceted. For example, MPN treatments may influence MetS development by inducing weight gain, a common side effect of JAK inhibitors such as ruxolitinib[<a href="#B62" class="usa-link" aria-describedby="B62">62</a>]. Furthermore, patients with MPNs often present with inflammation, which can also contribute to dyslipidemia and MetS. Chronic inflammation has been associated with insulin resistance, which is a key driver of MetS. MPN treatments such as ruxolitinib have potent anti-inflammatory effects, but can also affect metabolic homeostasis, leading to adverse metabolic effects[<a href="#B71" class="usa-link" aria-describedby="B71">71</a>].</p> <p>Although these potential side effects are concerning, it is important to note that the benefits of MPN therapy, including control of disease symptoms and improvement in survival, often outweigh these risks. However, these findings highlight the need for regular monitoring of serum lipid profiles and metabolic parameters in patients undergoing MPN treatment. They also emphasize the importance of lifestyle modifications, including diet and physical activity, to counteract these potential side effects. It is crucial that clinicians consider the possible impact of MPN treatments on serum lipid concentrations, dyslipidemia, and MetS. By closely monitoring these parameters, early intervention and educating patients about lifestyle changes, clinicians can help mitigate the risk of cardiovascular disease and improve the overall quality of life for patients with MPNs.</p></section><section id="sec5"><h2 class="pmc_sec_title">MOLECULAR MECHANISMS COMMON IN DYSLIPIDEMIA, METS AND MPNs</h2> <p>Clonal hematopoiesis is the process of equipotential cloning of hematopoietic stem cells (HSCs) with the aim of providing the body with a sufficient number of HSCs, therefore regulating the amount of its derivatives within the body[<a href="#B72" class="usa-link" aria-describedby="B72">72</a>,<a href="#B73" class="usa-link" aria-describedby="B73">73</a>]. The process is similar to that of regular cell division. However, since gene replication is prone to errors due to DNA derangement and telomere shortening, the fact that cells with higher potency offer a larger range of expressed genes means that any mutations within the replicated DNA will be expressed more frequently[<a href="#B73" class="usa-link" aria-describedby="B73">73</a>,<a href="#B74" class="usa-link" aria-describedby="B74">74</a>]. At the same time, telomere shortening reduces the production of enzymes that delay cell senescence, apoptosis, and decrease susceptibility to genetic mutations[<a href="#B75" class="usa-link" aria-describedby="B75">75</a>-<a href="#B78" class="usa-link" aria-describedby="B78">78</a>]. Researchers reported a correlation between telomere shortening and decline in stem cell function as people age[<a href="#B75" class="usa-link" aria-describedby="B75">75</a>,<a href="#B76" class="usa-link" aria-describedby="B76">76</a>]. Another study inversely proved that mice overexpressing telomeres showed that mice with longer telomeres had delayed aging and increased cancer resistance[<a href="#B79" class="usa-link" aria-describedby="B79">79</a>].</p> <p>As cells are always exposed to the environment, they continuously accumulate oxidative stress throughout their life[<a href="#B73" class="usa-link" aria-describedby="B73">73</a>]. Derangement may then be passed on to the next generation of cells: Causing transcription, translation, and proofreading to fail during DNA synthesis. This perpetuates to form a cycle where cells live to continuously accumulate derangements, only to be passed on later to the next generation of cells[<a href="#B73" class="usa-link" aria-describedby="B73">73</a>]. This explains why ‘degenerative’ diseases become more apparent as we age[<a href="#B73" class="usa-link" aria-describedby="B73">73</a>]. This process is called a somatic mutation, described as cellular level alteration in somatic tissues occurring after fertilization that does not involve the germline and consequently does not carry on to the offspring[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>].</p> <p>Exploring the root cause of DNA damage further, scientists have discovered that oxidative stress played a key role in causing derangements of the molecular composition within amino acids that form the DNA chain[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>,<a href="#B81" class="usa-link" aria-describedby="B81">81</a>]. Oxidative stress occurs due to an imbalance between reactive oxygen and nitrogen species and antioxidants within the body[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>-<a href="#B82" class="usa-link" aria-describedby="B82">82</a>]. It may be obtained internally as a byproduct of metabolism (which includes pathogen-caused inflammation) and externally from the environment. Eventually, these mutations can evolve from silent mutations into diseases deemed clinically significant[<a href="#B80" class="usa-link" aria-describedby="B80">80</a>-<a href="#B82" class="usa-link" aria-describedby="B82">82</a>].</p> <p>However, the occurrence of thrombotic events, particularly in young people, should warrant screening for blood cancers and especially MPNs. Mayerhofer <em>et al</em>[<a href="#B83" class="usa-link" aria-describedby="B83">83</a>] highlighted that young individuals who experience episodes of stroke display a three-times elevated prevalence of clonal hematopoiesis of indeterminate potential mutations and several suffer from MPNs and eventually need of cytoreduction treatment. Furthermore, they defined that these patients express a higher burden of atherosclerosis and an elevated carotid intima media thickness, reinforcing that there is pronounced endothelial dysfunction in MPNs[<a href="#B83" class="usa-link" aria-describedby="B83">83</a>,<a href="#B84" class="usa-link" aria-describedby="B84">84</a>]. It is well known that dyslipidemia aggravates atherogenesis and is associated with inflammation, oxidative stress, cytokines, and other molecular messengers to promote atherosclerosis, including in subjects with MPNs[<a href="#B85" class="usa-link" aria-describedby="B85">85</a>-<a href="#B87" class="usa-link" aria-describedby="B87">87</a>]. We have learned from murine models that laboratory mice that express the <em>JAK2V617F</em> mutation and suffer from dyslipidemia exhibit a myriad of aberrant molecular mechanisms that aggravate atherosclerosis, namely macrophage erythrophagocytosis, increased lipid peroxidation, p38 mitogen-activated protein kinase signaling and concentrations of pro-inflammatory chemokines, RBC-derived microvesicles and cytokines, endothelial damage, defective efferocytosis, inflammasome overactivation, ferroptosis, decreased levels of c-Mer tyrosine kinase, and expansion of preleukemic HSCs[<a href="#B88" class="usa-link" aria-describedby="B88">88</a>-<a href="#B91" class="usa-link" aria-describedby="B91">91</a>]. ATP-binding cassette sub-family G member 1 and ATP binding cassette subfamily A member 1, <em>i.e.</em> adenosine triphosphate-binding cassette transporters, N-acetyl cysteine, fedratinib, HDL-C, and simvastatin seem to alleviate atherogenesis, myelopoiesis, and endothelial dysfunction in <em>in vivo</em> assessments of <em>JAK2V617F</em>-positive mice[<a href="#B90" class="usa-link" aria-describedby="B90">90</a>,<a href="#B92" class="usa-link" aria-describedby="B92">92</a>,<a href="#B93" class="usa-link" aria-describedby="B93">93</a>]. These findings have been confirmed by investigations conducted in MPN subjects, as Skov <em>et al</em>[<a href="#B94" class="usa-link" aria-describedby="B94">94</a>] pointed out that in MPNs, there is a dysregulation of several genes involved in the development of atherosclerosis, for example downregulation of B-cell lymphoma 2 (Bcl-2) and upregulation of matrix metalloproteinase 1, Bcl-2-like protein 1, thrombospondin-4, and prostaglandin-endoperoxide synthase 1 is in PV, ET, and PMF[<a href="#B94" class="usa-link" aria-describedby="B94">94</a>]. Moreover, elevated variant allele frequencies of <em>JAK2V617F</em> and neutrophil-to-lymphocyte ratios are associated with notable inflammation, arterial stiffness, and atherosclerosis in MPNs[<a href="#B95" class="usa-link" aria-describedby="B95">95</a>-<a href="#B97" class="usa-link" aria-describedby="B97">97</a>]. Furthermore, in subjects with atherosclerosis, dyslipidemia is associated with increased concentrations of platelet-derived growth factor and other cytokines which are molecules known to stimulate proliferation of myeloid cells, and peripheral arterial disease, a vascular complication driven by lipid abnormalities and atherogenesis, has been shown along with atrial fibrillation to be a notable predictor of thrombotic and bleeding complications, as well as death in MPNs[<a href="#B98" class="usa-link" aria-describedby="B98">98</a>,<a href="#B99" class="usa-link" aria-describedby="B99">99</a>]. Thus, the crosstalk between dyslipidemia, inflammation, and oxidative stress may stimulate a process of accelerated atherosclerosis in MPNs and eventually results in higher rates of thrombotic and, in some cases, hemorrhagic complications in these hematological malignancies (Figure <a href="#F1" class="usa-link">1</a>)[<a href="#B100" class="usa-link" aria-describedby="B100">100</a>].</p> <figure class="fig xbox font-sm" id="F1"><h3 class="obj_head">Figure 1.</h3> <p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=11212607_WJCO-15-717-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9ea/11212607/a7fcc0cd6c70/WJCO-15-717-g001.jpg" loading="lazy" height="358" width="771" alt="Figure 1"></a></p> <div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <figcaption><p> <strong>Schematic representation of the interplay among dyslipidemia, atherosclerosis, and myeloproliferative neoplasms, with a focus on the main pathogenetic mechanisms that drive the development of atherosclerosis.</strong> CHIP: Clonal hematopoiesis of indeterminate potential; HSC: Hematopoietic stem cells; MPNs: Myeloproliferative neoplasms.</p></figcaption></figure></section><section id="sec6"><h2 class="pmc_sec_title">CONCLUSION</h2> <p>Lipid abnormalities trigger the development of atherosclerosis and work together with oxidative stress, inflammation, genetics, and a conundrum of molecules to increase the risk of thrombosis in MPNs. In addition, several drugs used in the treatment of these blood cancers, such as ruxolitinib or interferon-alpha, may alter the lipid profiles of MPN subjects. Thus, the interaction between dyslipidemia and MPNs appears complex and requires in-depth research in future studies that should evaluate the impact of dyslipidemia as a unique and potentially deleterious CVRF in these hematologic malignancies.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2> <div class="fn-group p font-secondary-light font-sm"> <div class="fn p" id="fn3"><p> <strong>Conflict-of-interest statement:</strong> Dr. Găman reports grants from the Competitiveness Operational Programme A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT, Grant Agreement No. 149/26.10.2016 (MySMIS2014+: 106774), during the conduct of the study. The other authors do not have any conflicts of interest to declare.</p></div> <div class="fn p" id="fn4"><p> <strong>Provenance and peer review:</strong> Invited article; Externally peer reviewed.</p></div> <div class="fn p" id="fn5"><p> <strong>Peer-review model:</strong> Single blind</p></div> <div class="fn p" id="fn6"><p> <strong>Corresponding Author's Membership in Professional Societies:</strong> Romanian Society of Hematology; Romanian Society of Pathophysiology; Romanian College of Physicians; International Society of Pathophysiology.</p></div> <div class="fn p" id="fn7"><p> <strong>Specialty type:</strong> Oncology</p></div> <div class="fn p" id="fn8"><p> <strong>Country of origin:</strong> Romania</p></div> <div class="fn p" id="fn9"><p> <strong>Peer-review report’s classification</strong> </p></div> <div class="fn p" id="fn10"><p> <strong>Scientific Quality:</strong> Grade C</p></div> <div class="fn p" id="fn11"><p> <strong>Novelty:</strong> Grade B</p></div> <div class="fn p" id="fn12"><p> <strong>Creativity or Innovation:</strong> Grade C</p></div> <div class="fn p" id="fn13"><p> <strong>Scientific Significance:</strong> Grade B</p></div> <div class="fn p" id="fn14"><p> <strong>P-Reviewer:</strong> Cigrovski Berkovic M, Croatia <strong>S-Editor:</strong> Li L <strong>L-Editor:</strong> Filipodia <strong>P-Editor:</strong> Zhao YQ</p></div> </div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2> <p>Mihnea-Alexandru Găman, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania; Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest 022328, Romania; Department of Cellular and Molecular Pathology, Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest 030304, Romania.</p> <p>Bahadar Singh Srichawla, Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.</p> <p>Yong-Feng Chen, Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China.</p> <p>Poulami Roy, Department of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India.</p> <p>Arkadeep Dhali, Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom.</p> <p>Ahmed Nahian, Lecom at Seton Hill, Greensburg, PA 15601, United States.</p> <p>Muhammad Romail Manan, Faculty of Medicine, Services Hospital, Lahore 54000, Pakistan.</p> <p>Vincent Kipkorir, Department of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya.</p> <p>Richard Christian Suteja, Faculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia.</p> <p>Lakshmi Venkata Simhachalam Kutikuppala, Department of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India.</p> <p>Amelia Maria Găman, Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania; Clinic of Hematology, Filantropia City Hospital, Craiova 200143, Romania. gamanamelia@yahoo.com.</p> <p>Camelia Cristina Diaconu, Department of Internal Medicine, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest 050474, Romania; Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest 105402, Romania.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2> <section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none"> <li id="B1"> <span class="label">1.</span><cite>Ghiaur G, Jones RJ. Hematopoiesis. Concise Guide to Hematology. 2019</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Concise%20Guide%20to%20Hematology&title=Hematopoiesis&author=G%20Ghiaur&author=RJ%20Jones&publication_year=2019&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B2"> <span class="label">2.</span><cite>Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15. doi: 10.1038/s41408-018-0054-y.</cite> [<a href="https://doi.org/10.1038/s41408-018-0054-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5807384/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29426921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&title=The%202016%20WHO%20classification%20and%20diagnostic%20criteria%20for%20myeloproliferative%20neoplasms:%20document%20summary%20and%20in-depth%20discussion&author=T%20Barbui&author=J%20Thiele&author=H%20Gisslinger&author=HM%20Kvasnicka&author=AM%20Vannucchi&volume=8&publication_year=2018&pages=15&pmid=29426921&doi=10.1038/s41408-018-0054-y&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B3"> <span class="label">3.</span><cite>Găman MA, Cozma MA, Dobrică EC, Crețoiu SM, Găman AM, Diaconu CC. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Life (Basel) 2021;11 doi: 10.3390/life11070677.</cite> [<a href="https://doi.org/10.3390/life11070677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8304270/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34357048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life%20(Basel)&title=Liquid%20Biopsy%20and%20Potential%20Liquid%20Biopsy-Based%20Biomarkers%20in%20Philadelphia-Negative%20Classical%20Myeloproliferative%20Neoplasms:%20A%20Systematic%20Review&author=MA%20G%C4%83man&author=MA%20Cozma&author=EC%20Dobric%C4%83&author=SM%20Cre%C8%9Boiu&author=AM%20G%C4%83man&volume=11&publication_year=2021&pmid=34357048&doi=10.3390/life11070677&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B4"> <span class="label">4.</span><cite>Easwar A, Siddon AJ. Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing. Life (Basel) 2021;11 doi: 10.3390/life11111158.</cite> [<a href="https://doi.org/10.3390/life11111158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8625510/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34833034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life%20(Basel)&title=Genetic%20Landscape%20of%20Myeloproliferative%20Neoplasms%20with%20an%20Emphasis%20on%20Molecular%20Diagnostic%20Laboratory%20Testing&author=A%20Easwar&author=AJ%20Siddon&volume=11&publication_year=2021&pmid=34833034&doi=10.3390/life11111158&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B5"> <span class="label">5.</span><cite>Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–770. doi: 10.1200/JCO.2010.31.8436.</cite> [<a href="https://doi.org/10.1200/JCO.2010.31.8436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4979120/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21205761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Philadelphia-negative%20classical%20myeloproliferative%20neoplasms:%20critical%20concepts%20and%20management%20recommendations%20from%20European%20LeukemiaNet&author=T%20Barbui&author=G%20Barosi&author=G%20Birgegard&author=F%20Cervantes&author=G%20Finazzi&volume=29&publication_year=2011&pages=761-770&pmid=21205761&doi=10.1200/JCO.2010.31.8436&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B6"> <span class="label">6.</span><cite>Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022;63:694–702. doi: 10.1080/10428194.2021.1992756.</cite> [<a href="https://doi.org/10.1080/10428194.2021.1992756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34689695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&title=Changes%20in%20the%20incidence%20and%20overall%20survival%20of%20patients%20with%20myeloproliferative%20neoplasms%20between%202002%20and%202016%20in%20the%20United%20States&author=S%20Verstovsek&author=J%20Yu&author=RM%20Scherber&author=S%20Verma&author=C%20Dieyi&volume=63&publication_year=2022&pages=694-702&pmid=34689695&doi=10.1080/10428194.2021.1992756&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B7"> <span class="label">7.</span><cite>Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171–173. doi: 10.1055/s-2006-939430.</cite> [<a href="https://doi.org/10.1055/s-2006-939430" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16673273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Thromb%20Hemost&title=Epidemiology%20of%20the%20myeloproliferative%20disorders%20polycythemia%20vera%20and%20essential%20thrombocythemia&author=P%20Johansson&volume=32&publication_year=2006&pages=171-173&pmid=16673273&doi=10.1055/s-2006-939430&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B8"> <span class="label">8.</span><cite>Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2011;2011:215–221. doi: 10.1182/asheducation-2011.1.215.</cite> [<a href="https://doi.org/10.1182/asheducation-2011.1.215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22160037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematology%20Am%20Soc%20Hematol%20Educ%20Program&title=Management%20of%20essential%20thrombocythemia&author=F%20Cervantes&volume=2011&publication_year=2011&pages=215-221&pmid=22160037&doi=10.1182/asheducation-2011.1.215&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B9"> <span class="label">9.</span><cite>Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015;1:97–105. doi: 10.1001/jamaoncol.2015.89.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2015.89" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26182311/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&title=Myeloproliferative%20Neoplasms:%20A%20Contemporary%20Review&author=A%20Tefferi&author=A%20Pardanani&volume=1&publication_year=2015&pages=97-105&pmid=26182311&doi=10.1001/jamaoncol.2015.89&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B10"> <span class="label">10.</span><cite>Torres DG, Paes J, da Costa AG, Malheiro A, Silva GV, Mourão LPS, Tarragô AM. JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms. Biomolecules. 2022;12 doi: 10.3390/biom12020291.</cite> [<a href="https://doi.org/10.3390/biom12020291" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8961666/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35204792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomolecules&title=JAK2%20Variant%20Signaling:%20Genetic,%20Hematologic%20and%20Immune%20Implication%20in%20Chronic%20Myeloproliferative%20Neoplasms&author=DG%20Torres&author=J%20Paes&author=Costa%20AG%20da&author=A%20Malheiro&author=GV%20Silva&volume=12&publication_year=2022&pmid=35204792&doi=10.3390/biom12020291&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B11"> <span class="label">11.</span><cite>Moisa C, Gaman MA, Diaconu CC, Gaman AM. Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia. Rev Chim. 2019;70:2822–2825.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Chim&title=Oxidative%20Stress%20Levels,%20JAK2V617F%20Mutational%20Status%20and%20Thrombotic%20Complications%20in%20Patients%20with%20Essential%20Thrombocythemia&author=C%20Moisa&author=MA%20Gaman&author=CC%20Diaconu&author=AM%20Gaman&volume=70&publication_year=2019&pages=2822-2825&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B12"> <span class="label">12.</span><cite>Wang D, Yu X, Sun Y, Lv Y, Li Y, Zhao P, Niu J, Zhang Y, Chen Y, Chen K, Chen Z, Liu W, Wang M, Hu X. Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2023;29:10760296231181117. doi: 10.1177/10760296231181117.</cite> [<a href="https://doi.org/10.1177/10760296231181117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10291540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37350087/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Appl%20Thromb%20Hemost&title=Incidence%20of%20Thrombosis%20at%20Different%20Sites%20During%20the%20Follow-Up%20Period%20in%20Essential%20Thrombocythemia:%20A%20Systematic%20Review%20and%20Meta-Analysis&author=D%20Wang&author=X%20Yu&author=Y%20Sun&author=Y%20Lv&author=Y%20Li&volume=29&publication_year=2023&pages=10760296231181117&pmid=37350087&doi=10.1177/10760296231181117&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B13"> <span class="label">13.</span><cite>Meier B, Burton JH. Myeloproliferative Disorders. Hematol Oncol Clin North Am. 2017;31:1029–1044. doi: 10.1016/j.hoc.2017.08.007.</cite> [<a href="https://doi.org/10.1016/j.hoc.2017.08.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29078922/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol%20Clin%20North%20Am&title=Myeloproliferative%20Disorders&author=B%20Meier&author=JH%20Burton&volume=31&publication_year=2017&pages=1029-1044&pmid=29078922&doi=10.1016/j.hoc.2017.08.007&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B14"> <span class="label">14.</span><cite>Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595–600. doi: 10.3109/10428194.2013.813500.</cite> [<a href="https://doi.org/10.3109/10428194.2013.813500" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23768070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&title=Epidemiology%20of%20myeloproliferative%20neoplasms%20in%20the%20United%20States&author=J%20Mehta&author=H%20Wang&author=SU%20Iqbal&author=R%20Mesa&volume=55&publication_year=2014&pages=595-600&pmid=23768070&doi=10.3109/10428194.2013.813500&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B15"> <span class="label">15.</span><cite>Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–297. doi: 10.1111/ejh.12256.</cite> [<a href="https://doi.org/10.1111/ejh.12256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24372927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Haematol&title=Epidemiology%20of%20myelofibrosis,%20essential%20thrombocythemia,%20and%20polycythemia%20vera%20in%20the%20European%20Union&author=O%20Moulard&author=J%20Mehta&author=J%20Fryzek&author=R%20Olivares&author=U%20Iqbal&volume=92&publication_year=2014&pages=289-297&pmid=24372927&doi=10.1111/ejh.12256&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B16"> <span class="label">16.</span><cite>Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz J, Salama ME, Abutalib SA. Hematology: Basic principles and practice. 8th. Philadelphia, PA: Elsevier, 2018.</cite> [<a href="https://scholar.google.com/scholar_lookup?Hoffman%20R,%20Benz%20EJ,%20Silberstein%20LE,%20Heslop%20H,%20Weitz%20J,%20Salama%20ME,%20Abutalib%20SA.%20Hematology:%20Basic%20principles%20and%20practice.%208th.%20Philadelphia,%20PA:%20Elsevier,%202018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B17"> <span class="label">17.</span><cite>Găman MA, Kipkorir V, Srichawla BS, Dhali A, Găman AM, Diaconu CC. Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Biomedicines. 2023;11 doi: 10.3390/biomedicines11020388.</cite> [<a href="https://doi.org/10.3390/biomedicines11020388" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9952891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36830925/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&title=Primary%20Arterial%20Hypertension%20and%20Drug-Induced%20Hypertension%20in%20Philadelphia-Negative%20Classical%20Myeloproliferative%20Neoplasms:%20A%20Systematic%20Review&author=MA%20G%C4%83man&author=V%20Kipkorir&author=BS%20Srichawla&author=A%20Dhali&author=AM%20G%C4%83man&volume=11&publication_year=2023&pmid=36830925&doi=10.3390/biomedicines11020388&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B18"> <span class="label">18.</span><cite>Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf ÅR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Björkholm M. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. J Clin Oncol. 2015;33:2288–2295. doi: 10.1200/JCO.2014.57.6652.</cite> [<a href="https://doi.org/10.1200/JCO.2014.57.6652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26033810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Risk%20and%20Cause%20of%20Death%20in%20Patients%20Diagnosed%20With%20Myeloproliferative%20Neoplasms%20in%20Sweden%20Between%201973%20and%202005:%20A%20Population-Based%20Study&author=M%20Hultcrantz&author=SR%20Wilkes&author=SY%20Kristinsson&author=TM%20Andersson&author=%C3%85R%20Derolf&volume=33&publication_year=2015&pages=2288-2295&pmid=26033810&doi=10.1200/JCO.2014.57.6652&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B19"> <span class="label">19.</span><cite>Găman MA, Cozma MA, Manan MR, Srichawla BS, Dhali A, Ali S, Nahian A, Elton AC, Simhachalam Kutikuppala LV, Suteja RC, Diebel S, Găman AM, Diaconu CC. Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature. World J Clin Oncol. 2023;14:99–116. doi: 10.5306/wjco.v14.i3.99.</cite> [<a href="https://doi.org/10.5306/wjco.v14.i3.99" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10052333/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37009527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Clin%20Oncol&title=Budd-Chiari%20syndrome%20in%20myeloproliferative%20neoplasms:%20A%20review%20of%20literature&author=MA%20G%C4%83man&author=MA%20Cozma&author=MR%20Manan&author=BS%20Srichawla&author=A%20Dhali&volume=14&publication_year=2023&pages=99-116&pmid=37009527&doi=10.5306/wjco.v14.i3.99&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B20"> <span class="label">20.</span><cite>Seguro FS, Teixeira LLC, da Rosa LI, da Silva WF, Nardinelli L, Bendit I, Rocha V. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis. 2020;49:667–672. doi: 10.1007/s11239-019-02029-y.</cite> [<a href="https://doi.org/10.1007/s11239-019-02029-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31898273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Risk%20factors%20and%20incidence%20of%20thrombosis%20in%20a%20Brazilian%20cohort%20of%20patients%20with%20Philadelphia-negative%20myeloproliferative%20neoplasms&author=FS%20Seguro&author=LLC%20Teixeira&author=Rosa%20LI%20da&author=Silva%20WF%20da&author=L%20Nardinelli&volume=49&publication_year=2020&pages=667-672&pmid=31898273&doi=10.1007/s11239-019-02029-y&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B21"> <span class="label">21.</span><cite>Moisă C, Găman M, Assani AD, Găman A. The evaluation of oxidative stress in patients with essential thrombocythemia treated with risk-adapted therapy. Arch Balk Med Union. 2018;53:529–534.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Balk%20Med%20Union&title=The%20evaluation%20of%20oxidative%20stress%20in%20patients%20with%20essential%20thrombocythemia%20treated%20with%20risk-adapted%20therapy&author=C%20Mois%C4%83&author=M%20G%C4%83man&author=AD%20Assani&author=A%20G%C4%83man&volume=53&publication_year=2018&pages=529-534&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B22"> <span class="label">22.</span><cite>Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19:243–252. doi: 10.1016/j.blre.2005.01.001.</cite> [<a href="https://doi.org/10.1016/j.blre.2005.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15963833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Rev&title=Risk-adapted%20therapy%20in%20essential%20thrombocythemia%20and%20polycythemia%20vera&author=G%20Finazzi&author=T%20Barbui&volume=19&publication_year=2005&pages=243-252&pmid=15963833&doi=10.1016/j.blre.2005.01.001&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B23"> <span class="label">23.</span><cite>Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Risk factors for arterial vs venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7:662. doi: 10.1038/s41408-017-0035-6.</cite> [<a href="https://doi.org/10.1038/s41408-017-0035-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5802551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29282357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&title=Risk%20factors%20for%20arterial%20vs%20venous%20thrombosis%20in%20polycythemia%20vera:%20a%20single%20center%20experience%20in%20587%20patients&author=S%20Cerquozzi&author=D%20Barraco&author=T%20Lasho&author=C%20Finke&author=CA%20Hanson&volume=7&publication_year=2017&pages=662&pmid=29282357&doi=10.1038/s41408-017-0035-6&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B24"> <span class="label">24.</span><cite>Barbui T, Masciulli A, Ghirardi A, Carobbio A. ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood. 2017;129:1226–1227. doi: 10.1182/blood-2016-11-752600.</cite> [<a href="https://doi.org/10.1182/blood-2016-11-752600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28028024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=ACE%20inhibitors%20and%20cytoreductive%20therapy%20in%20polycythemia%20vera&author=T%20Barbui&author=A%20Masciulli&author=A%20Ghirardi&author=A%20Carobbio&volume=129&publication_year=2017&pages=1226-1227&pmid=28028024&doi=10.1182/blood-2016-11-752600&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B25"> <span class="label">25.</span><cite>Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–1069. doi: 10.1038/s41375-018-0077-1.</cite> [<a href="https://doi.org/10.1038/s41375-018-0077-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5986069/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29515238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&title=Philadelphia%20chromosome-negative%20classical%20myeloproliferative%20neoplasms:%20revised%20management%20recommendations%20from%20European%20LeukemiaNet&author=T%20Barbui&author=A%20Tefferi&author=AM%20Vannucchi&author=F%20Passamonti&author=RT%20Silver&volume=32&publication_year=2018&pages=1057-1069&pmid=29515238&doi=10.1038/s41375-018-0077-1&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B26"> <span class="label">26.</span><cite>Accurso V, Santoro M, Mancuso S, Siragusa S. Cardiovascular risk factor in MPN patients. J Thromb Thrombolysis. 2020;50:640–641. doi: 10.1007/s11239-020-02049-z.</cite> [<a href="https://doi.org/10.1007/s11239-020-02049-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32002767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Cardiovascular%20risk%20factor%20in%20MPN%20patients&author=V%20Accurso&author=M%20Santoro&author=S%20Mancuso&author=S%20Siragusa&volume=50&publication_year=2020&pages=640-641&pmid=32002767&doi=10.1007/s11239-020-02049-z&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B27"> <span class="label">27.</span><cite>Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022;43:611–653. doi: 10.1210/endrev/bnab037.</cite> [<a href="https://doi.org/10.1210/endrev/bnab037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9277652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34676866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocr%20Rev&title=A%20Modern%20Approach%20to%20Dyslipidemia&author=AJ%20Berberich&author=RA%20Hegele&volume=43&publication_year=2022&pages=611-653&pmid=34676866&doi=10.1210/endrev/bnab037&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B28"> <span class="label">28.</span><cite>Santos HO, Kones R, Rumana U, Earnest CP, Izidoro LFM, Macedo RCO. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clin Ther. 2019;41:1780–1797. doi: 10.1016/j.clinthera.2019.06.002.</cite> [<a href="https://doi.org/10.1016/j.clinthera.2019.06.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31307832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Ther&title=Lipoprotein(a):%20Current%20Evidence%20for%20a%20Physiologic%20Role%20and%20the%20Effects%20of%20Nutraceutical%20Strategies&author=HO%20Santos&author=R%20Kones&author=U%20Rumana&author=CP%20Earnest&author=LFM%20Izidoro&volume=41&publication_year=2019&pages=1780-1797&pmid=31307832&doi=10.1016/j.clinthera.2019.06.002&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B29"> <span class="label">29.</span><cite>Santos HO, Earnest CP, Tinsley GM, Izidoro LFM, Macedo RCO. Small dense low-density lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies. Prog Cardiovasc Dis. 2020;63:503–509. doi: 10.1016/j.pcad.2020.04.009.</cite> [<a href="https://doi.org/10.1016/j.pcad.2020.04.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32353373/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prog%20Cardiovasc%20Dis&title=Small%20dense%20low-density%20lipoprotein-cholesterol%20(sdLDL-C):%20Analysis,%20effects%20on%20cardiovascular%20endpoints%20and%20dietary%20strategies&author=HO%20Santos&author=CP%20Earnest&author=GM%20Tinsley&author=LFM%20Izidoro&author=RCO%20Macedo&volume=63&publication_year=2020&pages=503-509&pmid=32353373&doi=10.1016/j.pcad.2020.04.009&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B30"> <span class="label">30.</span><cite>Fahed G, Aoun L, Bou Zerdan M, Allam S, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23 doi: 10.3390/ijms23020786.</cite> [<a href="https://doi.org/10.3390/ijms23020786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8775991/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35054972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&title=Metabolic%20Syndrome:%20Updates%20on%20Pathophysiology%20and%20Management%20in%202021&author=G%20Fahed&author=L%20Aoun&author=Zerdan%20M%20Bou&author=S%20Allam&author=Y%20Bouferraa&volume=23&publication_year=2022&pmid=35054972&doi=10.3390/ijms23020786&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B31"> <span class="label">31.</span><cite>Karra P, Winn M, Pauleck S, Bulsiewicz-Jacobsen A, Peterson L, Coletta A, Doherty J, Ulrich CM, Summers SA, Gunter M, Hardikar S, Playdon MC. Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome. Obesity (Silver Spring) 2022;30:1323–1334. doi: 10.1002/oby.23444.</cite> [<a href="https://doi.org/10.1002/oby.23444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9302704/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35785479/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Obesity%20(Silver%20Spring)&title=Metabolic%20dysfunction%20and%20obesity-related%20cancer:%20Beyond%20obesity%20and%20metabolic%20syndrome&author=P%20Karra&author=M%20Winn&author=S%20Pauleck&author=A%20Bulsiewicz-Jacobsen&author=L%20Peterson&volume=30&publication_year=2022&pages=1323-1334&pmid=35785479&doi=10.1002/oby.23444&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B32"> <span class="label">32.</span><cite>Bilgihan MT, Ciftciler R. The Effect of Obesity and Body Mass Index on Hematologic Malignancies. Metab Syndr Relat Disord. 2023;21:353–361. doi: 10.1089/met.2023.0048.</cite> [<a href="https://doi.org/10.1089/met.2023.0048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37410513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metab%20Syndr%20Relat%20Disord&title=The%20Effect%20of%20Obesity%20and%20Body%20Mass%20Index%20on%20Hematologic%20Malignancies&author=MT%20Bilgihan&author=R%20Ciftciler&volume=21&publication_year=2023&pages=353-361&pmid=37410513&doi=10.1089/met.2023.0048&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B33"> <span class="label">33.</span><cite>Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. J Hematol Oncol. 2020;13:129. doi: 10.1186/s13045-020-00963-6.</cite> [<a href="https://doi.org/10.1186/s13045-020-00963-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7528381/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32998735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&title=Low%20high-density%20lipoprotein%20and%20increased%20risk%20of%20several%20cancers:%202%20population-based%20cohort%20studies%20including%20116,728%20individuals&author=KM%20Pedersen&author=Y%20%C3%87olak&author=SE%20Bojesen&author=BG%20Nordestgaard&volume=13&publication_year=2020&pages=129&pmid=32998735&doi=10.1186/s13045-020-00963-6&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B34"> <span class="label">34.</span><cite>Zhang Y, Zhou Y, Wang Y, Teng G, Li D, Du C, Chen Y, Zhang H, Li Y, Fu L, Chen K, Bai J. Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model. Cancer Med. 2020;9:2096–2105. doi: 10.1002/cam4.2886.</cite> [<a href="https://doi.org/10.1002/cam4.2886" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7064115/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31994332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med&title=Thrombosis%20among%201537%20patients%20with%20JAK2(V617F)%20-mutated%20myeloproliferative%20neoplasms:%20Risk%20factors%20and%20development%20of%20a%20predictive%20model&author=Y%20Zhang&author=Y%20Zhou&author=Y%20Wang&author=G%20Teng&author=D%20Li&volume=9&publication_year=2020&pages=2096-2105&pmid=31994332&doi=10.1002/cam4.2886&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B35"> <span class="label">35.</span><cite>Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J. 2020;10:21. doi: 10.1038/s41408-020-0289-2.</cite> [<a href="https://doi.org/10.1038/s41408-020-0289-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7042364/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32098944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&title=Validation%20of%20the%20IPSET%20score%20for%20thrombosis%20in%20patients%20with%20prefibrotic%20myelofibrosis&author=P%20Guglielmelli&author=A%20Carobbio&author=E%20Rumi&author=Stefano%20V%20De&author=L%20Mannelli&volume=10&publication_year=2020&pages=21&pmid=32098944&doi=10.1038/s41408-020-0289-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B36"> <span class="label">36.</span><cite>García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R, On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers (Basel) 2022;14 doi: 10.3390/cancers14092331.</cite> [<a href="https://doi.org/10.3390/cancers14092331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9104306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35565461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&title=Impact%20of%20Individual%20Comorbidities%20on%20Survival%20of%20Patients%20with%20Myelofibrosis&author=M%20Garc%C3%ADa-Fortes&author=JC%20Hern%C3%A1ndez-Boluda&author=A%20%C3%81lvarez-Larr%C3%A1n&author=JM%20Raya&author=A%20Angona&volume=14&publication_year=2022&pmid=35565461&doi=10.3390/cancers14092331&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B37"> <span class="label">37.</span><cite>Accurso V, Santoro M, Mancuso S, Contrino AD, Casimiro P, Sardo M, Raso S, Di Piazza F, Perez A, Bono M, Russo A, Siragusa S. Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival. Mediterr J Hematol Infect Dis. 2020;12:e2020008. doi: 10.4084/MJHID.2020.008.</cite> [<a href="https://doi.org/10.4084/MJHID.2020.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6951352/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31934318/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mediterr%20J%20Hematol%20Infect%20Dis&title=Cardiovascular%20Risk%20in%20Essential%20Thrombocythemia%20and%20Polycythemia%20Vera:%20Thrombotic%20Risk%20and%20Survival&author=V%20Accurso&author=M%20Santoro&author=S%20Mancuso&author=AD%20Contrino&author=P%20Casimiro&volume=12&publication_year=2020&pages=e2020008&pmid=31934318&doi=10.4084/MJHID.2020.008&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B38"> <span class="label">38.</span><cite>Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis. 2011;2011:874146. doi: 10.1155/2011/874146.</cite> [<a href="https://doi.org/10.1155/2011/874146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3200304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22084670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thrombosis&title=Gender%20and%20Vascular%20Complications%20in%20the%20JAK2%20V617F-Positive%20Myeloproliferative%20Neoplasms&author=BL%20Stein&author=A%20Rademaker&author=JL%20Spivak&author=AR%20Moliterno&volume=2011&publication_year=2011&pages=874146&pmid=22084670&doi=10.1155/2011/874146&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B39"> <span class="label">39.</span><cite>Gu W, Zhang Y, Sun T, Ju M, Liu X, Xue F, Chen Y, Liu W, Li H, Wang W, Chi Y, Yang R, Fu R, Bai J, Zhang L. Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score system. Res Pract Thromb Haemost. 2023;7:100132. doi: 10.1016/j.rpth.2023.100132.</cite> [<a href="https://doi.org/10.1016/j.rpth.2023.100132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10126922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37113987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Res%20Pract%20Thromb%20Haemost&title=Prediction%20of%20thrombosis%20in%20polycythemia%20vera:%20Development%20and%20validation%20of%20a%20multiple%20factor-based%20prognostic%20score%C2%A0system&author=W%20Gu&author=Y%20Zhang&author=T%20Sun&author=M%20Ju&author=X%20Liu&volume=7&publication_year=2023&pages=100132&pmid=37113987&doi=10.1016/j.rpth.2023.100132&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B40"> <span class="label">40.</span><cite>Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2019;19:53–63. doi: 10.1016/j.clml.2018.08.020.</cite> [<a href="https://doi.org/10.1016/j.clml.2018.08.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30301673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lymphoma%20Myeloma%20Leuk&title=Influence%20of%20Blood%20Count,%20Cardiovascular%20Risks,%20Inherited%20Thrombophilia,%20and%20JAK2%20V617F%20Burden%20Allele%20on%20Type%20of%20Thrombosis%20in%20Patients%20With%20Philadelphia%20Chromosome%C2%A0Negative%20Myeloproliferative%20Neoplasms&author=I%20Horvat&author=A%20Boban&author=R%20Zadro&author=MR%20Antolic&author=R%20Serventi-Seiwerth&volume=19&publication_year=2019&pages=53-63&pmid=30301673&doi=10.1016/j.clml.2018.08.020&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B41"> <span class="label">41.</span><cite>Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis. 2023;55:263–272. doi: 10.1007/s11239-022-02751-0.</cite> [<a href="https://doi.org/10.1007/s11239-022-02751-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36484956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Reevaluation%20of%20cardiovascular%20risk%20factors%20for%20thrombotic%20events%20in%20580%20Japanese%20patients%20with%20essential%20thrombocythemia&author=C%20Furuya&author=Y%20Hashimoto&author=S%20Morishita&author=T%20Inano&author=T%20Ochiai&volume=55&publication_year=2023&pages=263-272&pmid=36484956&doi=10.1007/s11239-022-02751-0&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B42"> <span class="label">42.</span><cite>Košťál M, Schwarz J, Ovesná P, Penka M, Dulíček P for CZEMP-Czech Group for Ph- Myeloproliferative neoplasms. Ph(-) myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. J Thromb Thrombolysis. 2021;51:112–119. doi: 10.1007/s11239-020-02175-8.</cite> [<a href="https://doi.org/10.1007/s11239-020-02175-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32578055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Ph(-)%20myeloproliferative%20neoplasms%20and%20the%20related%20risk%20factors%20for%20stroke%20occurrence:%20Results%20from%20a%20registry%20of%20patients%20treated%20with%20Anagrelide&author=M%20Ko%C5%A1%C5%A5%C3%A1l&author=J%20Schwarz&author=P%20Ovesn%C3%A1&author=M%20Penka&author=P%20Dul%C3%AD%C4%8Dek&volume=51&publication_year=2021&pages=112-119&pmid=32578055&doi=10.1007/s11239-020-02175-8&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B43"> <span class="label">43.</span><cite>Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176–2184. doi: 10.1182/blood-2013-03-460154.</cite> [<a href="https://doi.org/10.1182/blood-2013-03-460154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23823316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=Myeloproliferative%20neoplasms%20and%20thrombosis&author=T%20Barbui&author=G%20Finazzi&author=A%20Falanga&volume=122&publication_year=2013&pages=2176-2184&pmid=23823316&doi=10.1182/blood-2013-03-460154&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B44"> <span class="label">44.</span><cite>Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232. doi: 10.1200/JCO.2005.07.062.</cite> [<a href="https://doi.org/10.1200/JCO.2005.07.062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15710945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Vascular%20and%20neoplastic%20risk%20in%20a%20large%20cohort%20of%20patients%20with%20polycythemia%20vera&author=R%20Marchioli&author=G%20Finazzi&author=R%20Landolfi&author=J%20Kutti&author=H%20Gisslinger&volume=23&publication_year=2005&pages=2224-2232&pmid=15710945&doi=10.1200/JCO.2005.07.062&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B45"> <span class="label">45.</span><cite>Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Akashi K, Matsumura I, Takenaka K, Komatsu N. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. Int J Hematol. 2022;115:208–221. doi: 10.1007/s12185-021-03253-0.</cite> [<a href="https://doi.org/10.1007/s12185-021-03253-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34727329/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Hematol&title=Clinical%20characteristics,%20prognostic%20factors,%20and%20outcomes%20of%20patients%20with%20essential%20thrombocythemia%20in%20Japan:%20the%20JSH-MPN-R18%20study&author=Y%20Hashimoto&author=T%20Ito&author=A%20Gotoh&author=M%20Nakamae&author=F%20Kimura&volume=115&publication_year=2022&pages=208-221&pmid=34727329&doi=10.1007/s12185-021-03253-0&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B46"> <span class="label">46.</span><cite>Chen J, Dong H, Fu R, Liu X, Xue F, Liu W, Chen Y, Sun T, Ju M, Dai X, Li H, Wang W, Chi Y, Yang R, Zhang L. Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia. J Thromb Thrombolysis. 2023;56:291–300. doi: 10.1007/s11239-023-02833-7.</cite> [<a href="https://doi.org/10.1007/s11239-023-02833-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37249742/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thromb%20Thrombolysis&title=Machine%20learning%20analyses%20constructed%20a%20novel%20model%20to%20predict%20recurrent%20thrombosis%20in%20adults%20with%20essential%20thrombocythemia&author=J%20Chen&author=H%20Dong&author=R%20Fu&author=X%20Liu&author=F%20Xue&volume=56&publication_year=2023&pages=291-300&pmid=37249742&doi=10.1007/s11239-023-02833-7&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B47"> <span class="label">47.</span><cite>Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol. 2021;39:409–418. doi: 10.1002/hon.2843.</cite> [<a href="https://doi.org/10.1002/hon.2843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33590502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&title=Impact%20of%20comorbidities%20and%20body%20mass%20index%20on%20the%20outcome%20of%20polycythemia%20vera%20patients&author=G%20Benevolo&author=EM%20Elli&author=D%20Bartoletti&author=R%20Latagliata&author=M%20Tiribelli&volume=39&publication_year=2021&pages=409-418&pmid=33590502&doi=10.1002/hon.2843&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B48"> <span class="label">48.</span><cite>Christensen SF, Scherber RM, Brochmann N, Goros M, Gelfond J, Andersen CL, Flachs EM, Mesa R. Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association. Cancers (Basel) 2020;12 doi: 10.3390/cancers12082202.</cite> [<a href="https://doi.org/10.3390/cancers12082202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7465643/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32781663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&title=Body%20Mass%20Index%20and%20Total%20Symptom%20Burden%20in%20Myeloproliferative%20Neoplasms%20Discovery%20of%20a%20U-shaped%20Association&author=SF%20Christensen&author=RM%20Scherber&author=N%20Brochmann&author=M%20Goros&author=J%20Gelfond&volume=12&publication_year=2020&pmid=32781663&doi=10.3390/cancers12082202&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B49"> <span class="label">49.</span><cite>Aswad MH, Kissova J, Ovesna P, Penka M. Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms. Neoplasma. 2021;68:1341–1350. doi: 10.4149/neo_2021_210729N1068.</cite> [<a href="https://doi.org/10.4149/neo_2021_210729N1068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34704452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasma&title=Risk%20factors%20of%20thrombosis%20in%20a%20cohort%20of%20206%20patients%20with%20BCR-ABL1%20negative%20myeloproliferative%20neoplasms&author=MH%20Aswad&author=J%20Kissova&author=P%20Ovesna&author=M%20Penka&volume=68&publication_year=2021&pages=1341-1350&pmid=34704452&doi=10.4149/neo_2021_210729N1068&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B50"> <span class="label">50.</span><cite>Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B. doi: 10.1016/s0002-9149(98)00033-2.</cite> [<a href="https://doi.org/10.1016/s0002-9149(98)00033-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9526809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&title=Hypertriglyceridemia,%20atherogenic%20dyslipidemia,%20and%20the%20metabolic%20syndrome&author=SM%20Grundy&volume=81&publication_year=1998&pages=18B-25B&pmid=9526809&doi=10.1016/s0002-9149(98)00033-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B51"> <span class="label">51.</span><cite>Manan MR, Kipkorir V, Nawaz I, Waithaka MW, Srichawla BS, Găman AM, Diaconu CC, Găman MA. Acute myocardial infarction in myeloproliferative neoplasms. World J Cardiol. 2023;15:571–581. doi: 10.4330/wjc.v15.i11.571.</cite> [<a href="https://doi.org/10.4330/wjc.v15.i11.571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10696206/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38058401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Cardiol&title=Acute%20myocardial%20infarction%20in%20myeloproliferative%20neoplasms&author=MR%20Manan&author=V%20Kipkorir&author=I%20Nawaz&author=MW%20Waithaka&author=BS%20Srichawla&volume=15&publication_year=2023&pages=571-581&pmid=38058401&doi=10.4330/wjc.v15.i11.571&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B52"> <span class="label">52.</span><cite>Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehz455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&title=2019%20ESC/EAS%20Guidelines%20for%20the%20management%20of%20dyslipidaemias:%20lipid%20modification%20to%20reduce%20cardiovascular%20risk&author=F%20Mach&author=C%20Baigent&author=AL%20Catapano&author=KC%20Koskinas&author=M%20Casula&volume=41&publication_year=2020&pages=111-188&pmid=31504418&doi=10.1093/eurheartj/ehz455&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B53"> <span class="label">53.</span><cite>Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26:364–373. doi: 10.1016/j.tcm.2015.10.004.</cite> [<a href="https://doi.org/10.1016/j.tcm.2015.10.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26654259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Cardiovasc%20Med&title=Metabolic%20syndrome%20update&author=SM%20Grundy&volume=26&publication_year=2016&pages=364-373&pmid=26654259&doi=10.1016/j.tcm.2015.10.004&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B54"> <span class="label">54.</span><cite>American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S34–S39. doi: 10.2337/dc21-S003.</cite> [<a href="https://doi.org/10.2337/dc21-S003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33298414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=3.%20Prevention%20or%20Delay%20of%20Type%202%20Diabetes:%20Standards%20of%20Medical%20Care%20in%20Diabetes-2021&volume=44&publication_year=2021&pages=S34-S39&pmid=33298414&doi=10.2337/dc21-S003&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B55"> <span class="label">55.</span><cite>Ge D, Gooljar SB, Kyriakou T, Collins LJ, Swaminathan R, Snieder H, Spector TD, O'Dell SD. Association of common JAK2 variants with body fat, insulin sensitivity and lipid profile. Obesity (Silver Spring) 2008;16:492–496. doi: 10.1038/oby.2007.79.</cite> [<a href="https://doi.org/10.1038/oby.2007.79" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2289869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18239666/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Obesity%20(Silver%20Spring)&title=Association%20of%20common%20JAK2%20variants%20with%20body%20fat,%20insulin%20sensitivity%20and%20lipid%20profile&author=D%20Ge&author=SB%20Gooljar&author=T%20Kyriakou&author=LJ%20Collins&author=R%20Swaminathan&volume=16&publication_year=2008&pages=492-496&pmid=18239666&doi=10.1038/oby.2007.79&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B56"> <span class="label">56.</span><cite>Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019;134:1832–1846. doi: 10.1182/blood.2019000162.</cite> [<a href="https://doi.org/10.1182/blood.2019000162" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6872961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31511238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=JAK2-mutant%20hematopoietic%20cells%20display%20metabolic%20alterations%20that%20can%20be%20targeted%20to%20treat%20myeloproliferative%20neoplasms&author=TN%20Rao&author=N%20Hansen&author=J%20Hilfiker&author=S%20Rai&author=JM%20Majewska&volume=134&publication_year=2019&pages=1832-1846&pmid=31511238&doi=10.1182/blood.2019000162&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B57"> <span class="label">57.</span><cite>Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316–331. doi: 10.1158/2159-8290.CD-14-0736.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-14-0736" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4355105/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25572172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&title=JAK-STAT%20pathway%20activation%20in%20malignant%20and%20nonmalignant%20cells%20contributes%20to%20MPN%20pathogenesis%20and%20therapeutic%20response&author=M%20Kleppe&author=M%20Kwak&author=P%20Koppikar&author=M%20Riester&author=M%20Keller&volume=5&publication_year=2015&pages=316-331&pmid=25572172&doi=10.1158/2159-8290.CD-14-0736&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B58"> <span class="label">58.</span><cite>Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Front Immunol. 2020;11:604142. doi: 10.3389/fimmu.2020.604142.</cite> [<a href="https://doi.org/10.3389/fimmu.2020.604142" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7734315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33329600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&title=Metabolic%20Vulnerabilities%20and%20Epigenetic%20Dysregulation%20in%20Myeloproliferative%20Neoplasms&author=V%20Sharma&author=KL%20Wright&author=PK%20Epling-Burnette&author=GW%20Reuther&volume=11&publication_year=2020&pages=604142&pmid=33329600&doi=10.3389/fimmu.2020.604142&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B59"> <span class="label">59.</span><cite>Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Investig. 2015;23:5–20. doi: 10.1515/hmbci-2015-0016.</cite> [<a href="https://doi.org/10.1515/hmbci-2015-0016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26057219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Horm%20Mol%20Biol%20Clin%20Investig&title=Adiponectin%20as%20a%20biomarker%20linking%20obesity%20and%20adiposopathy%20to%20hematologic%20malignancies&author=M%20Dalamaga&author=GS%20Christodoulatos&volume=23&publication_year=2015&pages=5-20&pmid=26057219&doi=10.1515/hmbci-2015-0016&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B60"> <span class="label">60.</span><cite>Repsold L, Joubert AM. Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders. Cells. 2021;10 doi: 10.3390/cells10113034.</cite> [<a href="https://doi.org/10.3390/cells10113034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8616365/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34831257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&title=Platelet%20Function,%20Role%20in%20Thrombosis,%20Inflammation,%20and%20Consequences%20in%20Chronic%20Myeloproliferative%20Disorders&author=L%20Repsold&author=AM%20Joubert&volume=10&publication_year=2021&pmid=34831257&doi=10.3390/cells10113034&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B61"> <span class="label">61.</span><cite>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–1801. doi: 10.1172/JCI29069.</cite> [<a href="https://doi.org/10.1172/JCI29069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1483173/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16823477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&title=Inflammation%20and%20insulin%20resistance&author=SE%20Shoelson&author=J%20Lee&author=AB%20Goldfine&volume=116&publication_year=2006&pages=1793-1801&pmid=16823477&doi=10.1172/JCI29069&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B62"> <span class="label">62.</span><cite>Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood. 2020;135:1062–1066. doi: 10.1182/blood.2019003050.</cite> [<a href="https://doi.org/10.1182/blood.2019003050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32047890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=Ruxolitinib%20can%20cause%20weight%20gain%20by%20blocking%20leptin%20signaling%20in%20the%20brain%20via%20JAK2/STAT3&author=N%20Moll%C3%A9&author=S%20Krichevsky&author=P%20Kermani&author=RT%20Silver&author=E%20Ritchie&volume=135&publication_year=2020&pages=1062-1066&pmid=32047890&doi=10.1182/blood.2019003050&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B63"> <span class="label">63.</span><cite>Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015;15:214–221.e1. doi: 10.1016/j.clml.2014.12.008.</cite> [<a href="https://doi.org/10.1016/j.clml.2014.12.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4418454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25682576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lymphoma%20Myeloma%20Leuk&title=Effects%20of%20ruxolitinib%20treatment%20on%20metabolic%20and%20nutritional%20parameters%20in%20patients%20with%20myelofibrosis%20from%20COMFORT-I&author=RA%20Mesa&author=S%20Verstovsek&author=V%20Gupta&author=JO%20Mascarenhas&author=E%20Atallah&volume=15&publication_year=2015&pages=214-221.e1&pmid=25682576&doi=10.1016/j.clml.2014.12.008&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B64"> <span class="label">64.</span><cite>Sapre M, Tremblay D, Wilck E, James A, Leiter A, Coltoff A, Koshy AG, Kremyanskaya M, Hoffman R, Mascarenhas JO, Gallagher EJ. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. Sci Rep. 2019;9:16609. doi: 10.1038/s41598-019-53056-x.</cite> [<a href="https://doi.org/10.1038/s41598-019-53056-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6851362/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31719581/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&title=Metabolic%20Effects%20of%20JAK1/2%20Inhibition%20in%20Patients%20with%20Myeloproliferative%20Neoplasms&author=M%20Sapre&author=D%20Tremblay&author=E%20Wilck&author=A%20James&author=A%20Leiter&volume=9&publication_year=2019&pages=16609&pmid=31719581&doi=10.1038/s41598-019-53056-x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B65"> <span class="label">65.</span><cite>Podoltsev N, Zhu M, Wang R, Zeidan AM, Wang X, Huntington SF, Giri S, Davidoff AJ, Gore SD, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study. Blood. 2018;132:4865–4865.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=Use%20of%20Statins,%20Survival%20and%20Incidence%20of%20Thrombosis%20Among%20Older%20Adults%20with%20Essential%20Thrombocythemia:%20A%20Population-Based%20Study&author=N%20Podoltsev&author=M%20Zhu&author=R%20Wang&author=AM%20Zeidan&author=X%20Wang&volume=132&publication_year=2018&pages=4865-4865&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B66"> <span class="label">66.</span><cite>Tuyet Kristensen D, Kisbye Øvlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, Hagemann Hilsøe M, Pommer Vallentin A, Brabrand M, Hasselbalch HC, El-Galaly TC, Stidsholt Roug A. Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv. 2023;7:3450–3457. doi: 10.1182/bloodadvances.2023009784.</cite> [<a href="https://doi.org/10.1182/bloodadvances.2023009784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10362262/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36877642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&title=Use%20of%20statins%20and%20risk%20of%20myeloproliferative%20neoplasms:%20a%20Danish%20nationwide%20case-control%20study&author=Kristensen%20D%20Tuyet&author=%C3%98vlisen%20A%20Kisbye&author=Kyneb%20Jakobsen%20L%20Hjort&author=Severinsen%20M%20Tang&author=LH%20Hannig&volume=7&publication_year=2023&pages=3450-3457&pmid=36877642&doi=10.1182/bloodadvances.2023009784&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B67"> <span class="label">67.</span><cite>Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. Am J Hematol. 2021;96:E200–E203. doi: 10.1002/ajh.26159.</cite> [<a href="https://doi.org/10.1002/ajh.26159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8250202/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33719144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hematol&title=Risk%20of%20infection%20in%20MPN%20patients%20in%20the%20era%20of%20Covid-19:%20A%20prospective%20multicenter%20study%20of%20257%20patients%20from%20the%20CML-MPN%20Quebec%20Research%20Group&author=K%20Simpson-Poirier&author=M%20Harnois&author=HJ%20Olney&author=S%20Sirhan&author=MO%20Gratton&volume=96&publication_year=2021&pages=E200-E203&pmid=33719144&doi=10.1002/ajh.26159&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B68"> <span class="label">68.</span><cite>Gao H, Wang H, Shan G, Liu R, Chen H, Sun S, Liu Y. Prevalence of dyslipidemia and associated risk factors among adult residents of Shenmu City, China. PLoS One. 2021;16:e0250573. doi: 10.1371/journal.pone.0250573.</cite> [<a href="https://doi.org/10.1371/journal.pone.0250573" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8104371/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33961634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Prevalence%20of%20dyslipidemia%20and%20associated%20risk%20factors%20among%20adult%20residents%20of%20Shenmu%20City,%20China&author=H%20Gao&author=H%20Wang&author=G%20Shan&author=R%20Liu&author=H%20Chen&volume=16&publication_year=2021&pages=e0250573&pmid=33961634&doi=10.1371/journal.pone.0250573&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B69"> <span class="label">69.</span><cite>Sung KC, Huh JH, Ryu S, Lee JY, Scorletti E, Byrne CD, Kim JY, Hyun DS, Ko SB. Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users. J Clin Med. 2019;8 doi: 10.3390/jcm8101571.</cite> [<a href="https://doi.org/10.3390/jcm8101571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6832139/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31581520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&title=Low%20Levels%20of%20Low-Density%20Lipoprotein%20Cholesterol%20and%20Mortality%20Outcomes%20in%20Non-Statin%20Users&author=KC%20Sung&author=JH%20Huh&author=S%20Ryu&author=JY%20Lee&author=E%20Scorletti&volume=8&publication_year=2019&pmid=31581520&doi=10.3390/jcm8101571&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B70"> <span class="label">70.</span><cite>Sun Y, Cai Y, Cen J, Zhu M, Pan J, Wang Q, Wu D, Chen S. Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World. Front Oncol. 2021;11:797825. doi: 10.3389/fonc.2021.797825.</cite> [<a href="https://doi.org/10.3389/fonc.2021.797825" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8724125/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34993148/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&title=Pegylated%20Interferon%20Alpha-2b%20in%20Patients%20With%20Polycythemia%20Vera%20and%20Essential%20Thrombocythemia%20in%20the%20Real%20World&author=Y%20Sun&author=Y%20Cai&author=J%20Cen&author=M%20Zhu&author=J%20Pan&volume=11&publication_year=2021&pages=797825&pmid=34993148&doi=10.3389/fonc.2021.797825&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B71"> <span class="label">71.</span><cite>Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9:7204–7218. doi: 10.18632/oncotarget.23208.</cite> [<a href="https://doi.org/10.18632/oncotarget.23208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5805548/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29467962/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&title=Inflammatory%20responses%20and%20inflammation-associated%20diseases%20in%20organs&author=L%20Chen&author=H%20Deng&author=H%20Cui&author=J%20Fang&author=Z%20Zuo&volume=9&publication_year=2018&pages=7204-7218&pmid=29467962&doi=10.18632/oncotarget.23208&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B72"> <span class="label">72.</span><cite>Watson CJ, Papula AL, Poon GYP, Wong WH, Young AL, Druley TE, Fisher DS, Blundell JR. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020;367:1449–1454. doi: 10.1126/science.aay9333.</cite> [<a href="https://doi.org/10.1126/science.aay9333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32217721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&title=The%20evolutionary%20dynamics%20and%20fitness%20landscape%20of%20clonal%20hematopoiesis&author=CJ%20Watson&author=AL%20Papula&author=GYP%20Poon&author=WH%20Wong&author=AL%20Young&volume=367&publication_year=2020&pages=1449-1454&pmid=32217721&doi=10.1126/science.aay9333&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B73"> <span class="label">73.</span><cite>Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98–105. doi: 10.1016/j.yjmcc.2021.07.004.</cite> [<a href="https://doi.org/10.1016/j.yjmcc.2021.07.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8629838/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34298011/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Cell%20Cardiol&title=Clonal%20hematopoiesis%20of%20indeterminate%20potential%20(CHIP):%20Linking%20somatic%20mutations,%20hematopoiesis,%20chronic%20inflammation%20and%20cardiovascular%20disease&author=CS%20Marnell&author=A%20Bick&author=P%20Natarajan&volume=161&publication_year=2021&pages=98-105&pmid=34298011&doi=10.1016/j.yjmcc.2021.07.004&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B74"> <span class="label">74.</span><cite>Rodríguez-Rodero S, Fernández-Morera JL, Menéndez-Torre E, Calvanese V, Fernández AF, Fraga MF. Aging genetics and aging. Aging Dis. 2011;2:186–195.</cite> [<a href="/articles/PMC3295054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22396873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aging%20Dis&title=Aging%20genetics%20and%20aging&author=S%20Rodr%C3%ADguez-Rodero&author=JL%20Fern%C3%A1ndez-Morera&author=E%20Men%C3%A9ndez-Torre&author=V%20Calvanese&author=AF%20Fern%C3%A1ndez&volume=2&publication_year=2011&pages=186-195&pmid=22396873&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B75"> <span class="label">75.</span><cite>Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–1138. doi: 10.1038/nm1006-1133.</cite> [<a href="https://doi.org/10.1038/nm1006-1133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17024208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=Telomeres%20and%20telomerase:%20the%20path%20from%20maize,%20Tetrahymena%20and%20yeast%20to%20human%20cancer%20and%20aging&author=EH%20Blackburn&author=CW%20Greider&author=JW%20Szostak&volume=12&publication_year=2006&pages=1133-1138&pmid=17024208&doi=10.1038/nm1006-1133&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B76"> <span class="label">76.</span><cite>Greenwood MJ, Lansdorp PM. Telomeres, telomerase, and hematopoietic stem cell biology. Arch Med Res. 2003;34:489–495. doi: 10.1016/j.arcmed.2003.07.003.</cite> [<a href="https://doi.org/10.1016/j.arcmed.2003.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14734088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Med%20Res&title=Telomeres,%20telomerase,%20and%20hematopoietic%20stem%20cell%20biology&author=MJ%20Greenwood&author=PM%20Lansdorp&volume=34&publication_year=2003&pages=489-495&pmid=14734088&doi=10.1016/j.arcmed.2003.07.003&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B77"> <span class="label">77.</span><cite>Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak K, Humphries SE. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis. 2010;209:42–50. doi: 10.1016/j.atherosclerosis.2009.09.070.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2009.09.070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2839074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19889414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&title=Association%20of%20telomere%20length%20with%20type%202%20diabetes,%20oxidative%20stress%20and%20UCP2%20gene%20variation&author=KD%20Salpea&author=PJ%20Talmud&author=JA%20Cooper&author=CG%20Maubaret&author=JW%20Stephens&volume=209&publication_year=2010&pages=42-50&pmid=19889414&doi=10.1016/j.atherosclerosis.2009.09.070&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B78"> <span class="label">78.</span><cite>von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27:339–344. doi: 10.1016/s0968-0004(02)02110-2.</cite> [<a href="https://doi.org/10.1016/s0968-0004(02)02110-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12114022/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Biochem%20Sci&title=Oxidative%20stress%20shortens%20telomeres&author=Zglinicki%20T%20von&volume=27&publication_year=2002&pages=339-344&pmid=12114022&doi=10.1016/s0968-0004(02)02110-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B79"> <span class="label">79.</span><cite>Tomás-Loba A, Flores I, Fernández-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell. 2008;135:609–622. doi: 10.1016/j.cell.2008.09.034.</cite> [<a href="https://doi.org/10.1016/j.cell.2008.09.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19013273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&title=Telomerase%20reverse%20transcriptase%20delays%20aging%20in%20cancer-resistant%20mice&author=A%20Tom%C3%A1s-Loba&author=I%20Flores&author=PJ%20Fern%C3%A1ndez-Marcos&author=ML%20Cayuela&author=A%20Maraver&volume=135&publication_year=2008&pages=609-622&pmid=19013273&doi=10.1016/j.cell.2008.09.034&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B80"> <span class="label">80.</span><cite>Miles B, Tadi P. Genetics, Somatic Mutation. 2023 Apr 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/32491819/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miles%20B,%20Tadi%20P.%20Genetics,%20Somatic%20Mutation.%202023%20Apr%2017.%20In:%20StatPearls%20%5BInternet%5D.%20Treasure%20Island%20(FL):%20StatPearls%20Publishing;%202024%20Jan-" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B81"> <span class="label">81.</span><cite>Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757–772. doi: 10.2147/CIA.S158513.</cite> [<a href="https://doi.org/10.2147/CIA.S158513" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5927356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29731617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Interv%20Aging&title=Oxidative%20stress,%20aging,%20and%20diseases&author=I%20Liguori&author=G%20Russo&author=F%20Curcio&author=G%20Bulli&author=L%20Aran&volume=13&publication_year=2018&pages=757-772&pmid=29731617&doi=10.2147/CIA.S158513&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B82"> <span class="label">82.</span><cite>Salisbury D, Bronas U. Reactive oxygen and nitrogen species: impact on endothelial dysfunction. Nurs Res. 2015;64:53–66. doi: 10.1097/NNR.0000000000000068.</cite> [<a href="https://doi.org/10.1097/NNR.0000000000000068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25502061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nurs%20Res&title=Reactive%20oxygen%20and%20nitrogen%20species:%20impact%20on%20endothelial%20dysfunction&author=D%20Salisbury&author=U%20Bronas&volume=64&publication_year=2015&pages=53-66&pmid=25502061&doi=10.1097/NNR.0000000000000068&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B83"> <span class="label">83.</span><cite>Mayerhofer E, Strecker C, Becker H, Georgakis MK, Uddin MM, Hoffmann MM, Nadarajah N, Meggendorfer M, Haferlach T, Rosand J, Natarajan P, Anderson CD, Harloff A, Hoermann G. Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke. Stroke. 2023;54:938–946. doi: 10.1161/STROKEAHA.122.041416.</cite> [<a href="https://doi.org/10.1161/STROKEAHA.122.041416" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10050122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36789775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Stroke&title=Prevalence%20and%20Therapeutic%20Implications%20of%20Clonal%20Hematopoiesis%20of%20Indeterminate%20Potential%20in%20Young%20Patients%20With%20Stroke&author=E%20Mayerhofer&author=C%20Strecker&author=H%20Becker&author=MK%20Georgakis&author=MM%20Uddin&volume=54&publication_year=2023&pages=938-946&pmid=36789775&doi=10.1161/STROKEAHA.122.041416&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B84"> <span class="label">84.</span><cite>Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM. Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. J Clin Med. 2021;11 doi: 10.3390/jcm11010013.</cite> [<a href="https://doi.org/10.3390/jcm11010013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8745571/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35011753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&title=Covert%20Brain%20Infarcts%20in%20Patients%20with%20Philadelphia%20Chromosome-Negative%20Myeloproliferative%20Disorders&author=PI%20Kuznetsova&author=AA%20Raskurazhev&author=RN%20Konovalov&author=MV%20Krotenkova&author=AO%20Chechetkin&volume=11&publication_year=2021&pmid=35011753&doi=10.3390/jcm11010013&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B85"> <span class="label">85.</span><cite>Xiang Q, Tian F, Xu J, Du X, Zhang S, Liu L. New insight into dyslipidemia-induced cellular senescence in atherosclerosis. Biol Rev Camb Philos Soc. 2022;97:1844–1867. doi: 10.1111/brv.12866.</cite> [<a href="https://doi.org/10.1111/brv.12866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9541442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35569818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Rev%20Camb%20Philos%20Soc&title=New%20insight%20into%20dyslipidemia-induced%20cellular%20senescence%20in%20atherosclerosis&author=Q%20Xiang&author=F%20Tian&author=J%20Xu&author=X%20Du&author=S%20Zhang&volume=97&publication_year=2022&pages=1844-1867&pmid=35569818&doi=10.1111/brv.12866&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B86"> <span class="label">86.</span><cite>Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225. doi: 10.1182/blood-2011-11-394775.</cite> [<a href="https://doi.org/10.1182/blood-2011-11-394775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22318201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&title=Perspectives%20on%20chronic%20inflammation%20in%20essential%20thrombocythemia,%20polycythemia%20vera,%20and%20myelofibrosis:%20is%20chronic%20inflammation%20a%20trigger%20and%20driver%20of%20clonal%20evolution%20and%20development%20of%20accelerated%20atherosclerosis%20and%20second%20cancer?&author=HC%20Hasselbalch&volume=119&publication_year=2012&pages=3219-3225&pmid=22318201&doi=10.1182/blood-2011-11-394775&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B87"> <span class="label">87.</span><cite>Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021;42:4389–4400. doi: 10.1093/eurheartj/ehab447.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehab447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8572559/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34343257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&title=The%20JAK-STAT%20pathway:%20an%20emerging%20target%20for%20cardiovascular%20disease%20in%20rheumatoid%20arthritis%20and%20myeloproliferative%20neoplasms&author=C%20Baldini&author=FR%20Moriconi&author=S%20Galimberti&author=P%20Libby&author=Caterina%20R%20De&volume=42&publication_year=2021&pages=4389-4400&pmid=34343257&doi=10.1093/eurheartj/ehab447&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B88"> <span class="label">88.</span><cite>Liu W, Östberg N, Yalcinkaya M, Dou H, Endo-Umeda K, Tang Y, Hou X, Xiao T, Fidler TP, Abramowicz S, Yang YG, Soehnlein O, Tall AR, Wang N. Erythroid lineage Jak2V617F expression promotes atherosclerosis through erythrophagocytosis and macrophage ferroptosis. J Clin Invest. 2022;132 doi: 10.1172/JCI155724.</cite> [<a href="https://doi.org/10.1172/JCI155724" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9246386/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35587375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&title=Erythroid%20lineage%20Jak2V617F%20expression%20promotes%20atherosclerosis%20through%20erythrophagocytosis%20and%20macrophage%20ferroptosis&author=W%20Liu&author=N%20%C3%96stberg&author=M%20Yalcinkaya&author=H%20Dou&author=K%20Endo-Umeda&volume=132&publication_year=2022&pmid=35587375&doi=10.1172/JCI155724&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B89"> <span class="label">89.</span><cite>Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, Welch C, Cai B, Silvestre-Roig C, Ai D, Yang YG, Hidalgo A, Soehnlein O, Tabas I, Levine RL, Tall AR, Wang N. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 (V617F) Mice. Circ Res. 2018;123:e35–e47. doi: 10.1161/CIRCRESAHA.118.313283.</cite> [<a href="https://doi.org/10.1161/CIRCRESAHA.118.313283" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6309796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30571460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Res&title=Macrophage%20Inflammation,%20Erythrophagocytosis,%20and%20Accelerated%20Atherosclerosis%20in%20Jak2%20(V617F)%20Mice&author=W%20Wang&author=W%20Liu&author=T%20Fidler&author=Y%20Wang&author=Y%20Tang&volume=123&publication_year=2018&pages=e35-e47&pmid=30571460&doi=10.1161/CIRCRESAHA.118.313283&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B90"> <span class="label">90.</span><cite>Poisson J, Tanguy M, Davy H, Camara F, El Mdawar MB, Kheloufi M, Dagher T, Devue C, Lasselin J, Plessier A, Merchant S, Blanc-Brude O, Souyri M, Mougenot N, Dingli F, Loew D, Hatem SN, James C, Villeval JL, Boulanger CM, Rautou PE. Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. J Clin Invest. 2020;130:2630–2643. doi: 10.1172/JCI124566.</cite> [<a href="https://doi.org/10.1172/JCI124566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7190923/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32045382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&title=Erythrocyte-derived%20microvesicles%20induce%20arterial%20spasms%20in%20JAK2V617F%20myeloproliferative%20neoplasm&author=J%20Poisson&author=M%20Tanguy&author=H%20Davy&author=F%20Camara&author=Mdawar%20MB%20El&volume=130&publication_year=2020&pages=2630-2643&pmid=32045382&doi=10.1172/JCI124566&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B91"> <span class="label">91.</span><cite>Majeti R, Jamieson C, Pang WW, Jaiswal S, Leeper NJ, Wernig G, Weissman IL. Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells. Annu Rev Med. 2022;73:307–320. doi: 10.1146/annurev-med-042420-104436.</cite> [<a href="https://doi.org/10.1146/annurev-med-042420-104436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35084991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Med&title=Clonal%20Expansion%20of%20Stem/Progenitor%20Cells%20in%20Cancer,%20Fibrotic%20Diseases,%20and%20Atherosclerosis,%20and%20CD47%20Protection%20of%20Pathogenic%20Cells&author=R%20Majeti&author=C%20Jamieson&author=WW%20Pang&author=S%20Jaiswal&author=NJ%20Leeper&volume=73&publication_year=2022&pages=307-320&pmid=35084991&doi=10.1146/annurev-med-042420-104436&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B92"> <span class="label">92.</span><cite>Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328:1689–1693. doi: 10.1126/science.1189731.</cite> [<a href="https://doi.org/10.1126/science.1189731" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3032591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20488992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&title=ATP-binding%20cassette%20transporters%20and%20HDL%20suppress%20hematopoietic%20stem%20cell%20proliferation&author=L%20Yvan-Charvet&author=T%20Pagler&author=EL%20Gautier&author=S%20Avagyan&author=RL%20Siry&volume=328&publication_year=2010&pages=1689-1693&pmid=20488992&doi=10.1126/science.1189731&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B93"> <span class="label">93.</span><cite>Tang Y, Liu W, Wang W, Fidler T, Woods B, Levine RL, Tall AR, Wang N. Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe(-/-) Mice. Cardiovasc Drugs Ther. 2020;34:145–152. doi: 10.1007/s10557-020-06943-9.</cite> [<a href="https://doi.org/10.1007/s10557-020-06943-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7125070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32086626/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Drugs%20Ther&title=Inhibition%20of%20JAK2%20Suppresses%20Myelopoiesis%20and%20Atherosclerosis%20in%20Apoe(-/-)%20Mice&author=Y%20Tang&author=W%20Liu&author=W%20Wang&author=T%20Fidler&author=B%20Woods&volume=34&publication_year=2020&pages=145-152&pmid=32086626&doi=10.1007/s10557-020-06943-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B94"> <span class="label">94.</span><cite>Skov V, Thomassen M, Kjaer L, Larsen MK, Knudsen TA, Ellervik C, Kruse TA, Hasselbalch HC. Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms. Eur J Haematol. 2023;111:805–814. doi: 10.1111/ejh.14081.</cite> [<a href="https://doi.org/10.1111/ejh.14081" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37640394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Haematol&title=Whole%20blood%20transcriptional%20profiling%20reveals%20highly%20deregulated%20atherosclerosis%20genes%20in%20Philadelphia-chromosome%20negative%20myeloproliferative%20neoplasms&author=V%20Skov&author=M%20Thomassen&author=L%20Kjaer&author=MK%20Larsen&author=TA%20Knudsen&volume=111&publication_year=2023&pages=805-814&pmid=37640394&doi=10.1111/ejh.14081&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B95"> <span class="label">95.</span><cite>Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, Sørensen AL, Ellervik C, Hasselbalch H, Bruun NE. High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2023;111:400–406. doi: 10.1111/ejh.14019.</cite> [<a href="https://doi.org/10.1111/ejh.14019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37286366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Haematol&title=High%20JAK2V617F%20variant%20allele%20frequency%20is%20associated%20with%20coronary%20artery%20but%20not%20aortic%20valve%20calcifications%20in%20patients%20with%20Philadelphia-negative%20myeloproliferative%20neoplasms&author=CN%20Solli&author=S%20Chamat-Hedemand&author=H%20Elming&author=A%20Ngo&author=L%20Kjaer&volume=111&publication_year=2023&pages=400-406&pmid=37286366&doi=10.1111/ejh.14019&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B96"> <span class="label">96.</span><cite>Kwon SS, Yoon SY, Jeong SY, Lee MY, Kim KH, Lee N, Won JH. Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera. Nutr Metab Cardiovasc Dis. 2022;32:1913–1916. doi: 10.1016/j.numecd.2022.04.013.</cite> [<a href="https://doi.org/10.1016/j.numecd.2022.04.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35606226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutr%20Metab%20Cardiovasc%20Dis&title=Neutrophil-lymphocyte%20ratio%20and%20carotid%20plaque%20burden%20in%20patients%20with%20essential%20thrombocythemia%20and%20polycythemia%20vera&author=SS%20Kwon&author=SY%20Yoon&author=SY%20Jeong&author=MY%20Lee&author=KH%20Kim&volume=32&publication_year=2022&pages=1913-1916&pmid=35606226&doi=10.1016/j.numecd.2022.04.013&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B97"> <span class="label">97.</span><cite>Anžič Drofenik A, Vrtovec M, Božič Mijovski M, Sever M, Preložnik Zupan I, Kejžar N, Blinc A. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Atherosclerosis. 2020;296:25–31. doi: 10.1016/j.atherosclerosis.2020.01.001.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2020.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32005002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&title=Progression%20of%20coronary%20calcium%20burden%20and%20carotid%20stiffness%20in%20patients%20with%20essential%20thrombocythemia%20associated%20with%20JAK2%20V617F%20mutation&author=Drofenik%20A%20An%C5%BEi%C4%8D&author=M%20Vrtovec&author=Mijovski%20M%20Bo%C5%BEi%C4%8D&author=M%20Sever&author=Zupan%20I%20Prelo%C5%BEnik&volume=296&publication_year=2020&pages=25-31&pmid=32005002&doi=10.1016/j.atherosclerosis.2020.01.001&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B98"> <span class="label">98.</span><cite>Jalkanen J, Hollmén M, Maksimow M, Jalkanen S, Hakovirta H. Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine. 2019;114:74–80. doi: 10.1016/j.cyto.2018.11.001.</cite> [<a href="https://doi.org/10.1016/j.cyto.2018.11.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30442459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine&title=Serum%20cytokine%20levels%20differ%20according%20to%20major%20cardiovascular%20risk%20factors%20in%20patients%20with%20lower%20limb%20atherosclerosis&author=J%20Jalkanen&author=M%20Hollm%C3%A9n&author=M%20Maksimow&author=S%20Jalkanen&author=H%20Hakovirta&volume=114&publication_year=2019&pages=74-80&pmid=30442459&doi=10.1016/j.cyto.2018.11.001&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B99"> <span class="label">99.</span><cite>Herbreteau L, Couturaud F, Hoffmann C, Bressollette L, Pan-Petesch B, Rio L, Lippert E, Ianotto JC. Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis. Thromb Res. 2023;226:93–99. doi: 10.1016/j.thromres.2023.04.021.</cite> [<a href="https://doi.org/10.1016/j.thromres.2023.04.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37141796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Res&title=Atrial%20fibrillation%20and%20peripheral%20arterial%20disease%20define%20MPN%20patients%20with%20very%20high%20risk%20of%20thrombosis&author=L%20Herbreteau&author=F%20Couturaud&author=C%20Hoffmann&author=L%20Bressollette&author=B%20Pan-Petesch&volume=226&publication_year=2023&pages=93-99&pmid=37141796&doi=10.1016/j.thromres.2023.04.021&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B100"> <span class="label">100.</span><cite>Gaman AM, Moisa C, Diaconu CC, Gaman MA. Crosstalk between Oxidative Stress, Chronic Inflammation and Disease Progression in Essential Thrombocythemia. Rev Chim. 2019;70:3486–3489.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Chim&title=Crosstalk%20between%20Oxidative%20Stress,%20Chronic%20Inflammation%20and%20Disease%20Progression%20in%20Essential%20Thrombocythemia&author=AM%20Gaman&author=C%20Moisa&author=CC%20Diaconu&author=MA%20Gaman&volume=70&publication_year=2019&pages=3486-3489&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> </ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless"> <p>Articles from World Journal of Clinical Oncology are provided here courtesy of <strong>Baishideng Publishing Group Inc</strong></p></footer></section></article> </main> </div> </div> </div>  <div class="pmc-sidenav desktop:grid-col-4 display-flex"> <section class="pmc-sidenav__container" aria-label="Article resources and navigation"> <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled"> <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" /> </button> <div class="display-none desktop:display-block"> <section class="margin-top-4 desktop:margin-top-0"> <h2 class="margin-top-0">ACTIONS</h2> <ul class="usa-list usa-list--unstyled usa-list--actions"> <li> <a href="https://doi.org/10.5306/wjco.v15.i6.717" class="usa-button usa-button--outline width-24 font-xs usa-link--external padding-left-0 padding-right-0" target="_blank" rel="noreferrer noopener" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_desktop" > <span class="height-3 display-inline-flex flex-align-center">View on publisher site</span> </a> </li> <li> <a href="pdf/WJCO-15-717.pdf" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">PDF (748.8 KB)</span> </a> </li> <li> <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_desktop" data-all-citations-url="/resources/citations/11212607/" data-citation-style="nlm" data-download-format-link="/resources/citations/11212607/export/" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span> </button> </li> <li> <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_desktop" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11212607%2F%23open-collections-dialog" data-in-collections="false"> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">Collections</span> </button> </li> <li class="pmc-permalink"> <button type="button" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11212607/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11212607/"> <h2 class="margin-top-0">RESOURCES</h2> <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-similar-articles" data-ga-category="resources_accordion" data-ga-action="open_similar_articles" data-ga-label="/articles/PMC11212607/" data-action-open="open_similar_articles" data-action-close="close_similar_articles" > Similar articles </button> </h3> <div id="resources-similar-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/similar-article-links/38946827/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-cited-by-other-articles" data-ga-category="resources_accordion" data-ga-action="open_cited_by" data-ga-label="/articles/PMC11212607/" data-action-open="open_cited_by" data-action-close="close_cited_by" > Cited by other articles </button> </h3> <div id="resources-cited-by-other-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/cited-by-links/38946827/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-links-to-ncbi-databases" data-ga-category="resources_accordion" data-ga-action="open_NCBI_links" data-ga-label="/articles/PMC11212607/" data-action-open="open_NCBI_links" data-action-close="close_NCBI_link" > Links to NCBI Databases </button> </h3> <div id="resources-links-to-ncbi-databases" class="usa-accordion__content usa-prose" data-source-url="/resources/db-links/11212607/" > </div> </div> </section> <section class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4" data-title-text="On this page" data-title-heading-level="h2" data-scroll-offset="0" data-root-margin="-10% 0px -80% 0px" data-main-content-selector="main" data-threshold="1" hidden ></section> </section> </div> <div class="overlay" role="dialog" aria-label="Citation Dialog" hidden> <div class="dialog citation-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Cite</h2> <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto" tabindex="1"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="citation-text-block"> <div class="citation-text margin-bottom-2"></div> <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center"> <li> <button class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus" data-ga-category="save_share" data-ga-action="cite" data-ga-label="copy" tabindex="2"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span>Copy</span> </button> </li> <li> <a href="#" role="button" class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button" data-ga-category="save_share" data-ga-action="cite" data-ga-label="download" title="Download a file for external citation management software" tabindex="3"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-none mobile-lg:display-inline">Download .nbib</span> <span class="display-inline mobile-lg:display-none">.nbib</span> </a> </li> <li> <div class="display-inline-flex flex-align-center"> <label class="usa-label margin-top-0">Format:</label> <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" > <option data-style-url-name="ama" value="AMA" > AMA </option> <option data-style-url-name="apa" value="APA" > APA </option> <option data-style-url-name="mla" value="MLA" > MLA </option> <option data-style-url-name="nlm" value="NLM" selected="selected"> NLM </option> </select> </div> </li> </ul> </div> </div> </div> <div class="overlay" role="dialog" hidden> <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Add to Collections</h2> </div> <div class="collections-action-panel action-panel"> <form id="collections-action-dialog-form" class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors" data-existing-collections-url="/list-existing-collections/" data-add-to-existing-collection-url="/add-to-existing-collection/" data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/" data-myncbi-max-collection-name-length="100" data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"> <input type="hidden" name="csrfmiddlewaretoken" value="h8KsUrWZOkGCZHh7Qq3eDbeKy5b2FjusdV9luLt6IjEcFtEAvLGarAh9UlfWHsnM"> <fieldset class="usa-fieldset margin-bottom-2"> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-new" class="usa-radio__input usa-radio__input--tile collections-new margin-top-0" name="collections" value="new" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_new" /> <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label> </div> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-existing" class="usa-radio__input usa-radio__input--tile collections-existing" name="collections" value="existing" checked="true" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_existing" /> <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label> </div> </fieldset> <fieldset class="usa-fieldset margin-bottom-2"> <div class="action-panel-control-wrap new-collections-controls"> <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0"> Name your collection <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr> </label> <input type="text" name="add-to-new-collection" id="collections-action-dialog-add-to-new" class="usa-input collections-action-add-to-new" pattern="[^"&=<>/]*" title="The following characters are not allowed in the Name field: "&=<>/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection" required /> </div> <div class="action-panel-control-wrap existing-collections-controls"> <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0"> Choose a collection </label> <select id="collections-action-dialog-add-to-existing" class="usa-select collections-action-add-to-existing" data-ga-category="collections_button" data-ga-action="select_collection" data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'"> </select> <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message"> Unable to load your collection due to an error<br> <a href="#">Please try again</a> </div> </div> </fieldset> <div class="display-inline-flex"> <button class="usa-button margin-top-0 action-panel-submit" type="submit" data-loading-label="Adding..." data-pinger-ignore data-ga-category="collections_button" data-ga-action="click" data-ga-label="add"> Add </button> <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel" aria-label="Close 'Add to Collections' panel" ref="linksrc=close_collections_panel" data-ga-category="collections_button" data-ga-action="click" data-ga-label="cancel"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class="ncbi-footer ncbi-dark-background " > <div class="ncbi-footer__icon-section"> <div class="ncbi-footer__social-header"> Follow NCBI </div> <div class="grid-container ncbi-footer__ncbi-social-icons-container"> <a href="https://twitter.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="40" height="40" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span> </a> <a href="https://www.facebook.com/ncbi.nlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="16" height="29" focusable="false" aria-hidden="true" viewBox="0 0 16 29" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z"> </path> </svg> <span class="usa-sr-only">NCBI on Facebook</span> </a> <a href="https://www.linkedin.com/company/ncbinlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="25" height="23" viewBox="0 0 26 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z"> </path> <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z"> </path> <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z"> </path> </svg> <span class="usa-sr-only">NCBI on LinkedIn</span> </a> <a href="https://github.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="28" height="27" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z"> </path> </svg> <span class="usa-sr-only">NCBI on GitHub</span> </a> <a href="https://ncbiinsights.ncbi.nlm.nih.gov/" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="26" height="26" viewBox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z"> </path> <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z"> </path> <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z"> </path> </svg> <span class="usa-sr-only">NCBI RSS feed</span> </a> </div> </div> <div data-testid="gridContainer" class="grid-container ncbi-footer__container"> <div class="grid-row ncbi-footer__main-content-container" data-testid="grid"> <div class="ncbi-footer__column"> <p class="ncbi-footer__circled-icons-heading"> Connect with NLM </p> <div class="ncbi-footer__circled-icons-list"> <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="32" height="32" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span> </a> <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="13" height="24" viewBox="0 0 13 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z"> </path> </svg> <span class="usa-sr-only">NLM on Facebook</span> </a> <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="21" height="15" viewBox="0 0 21 15" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z" fill="white" /> </svg> <span class="usa-sr-only">NLM on YouTube</span> </a> </div> </div> <address class="ncbi-footer__address ncbi-footer__column"> <p> <a class="usa-link usa-link--external" href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323" rel="noopener noreferrer" target="_blank">National Library of Medicine <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a> </p> </address> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link usa-link--alt ncbi-footer__link" > Web Policies </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link usa-link--alt ncbi-footer__link" > FOIA </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS Vulnerability Disclosure </a> </li> </ul> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://support.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > Help </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link usa-link--alt ncbi-footer__link" > Accessibility </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link usa-link--alt ncbi-footer__link" > Careers </a> </li> </ul> </div> <div class="grid-row grid-col-12" data-testid="grid"> <ul class="ncbi-footer__bottom-links-list"> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NLM </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NIH </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > USA.gov </a> </li> </ul> </div> </div> </footer> <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script> <button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top"> <label>Back to Top</label> <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#arrow_upward"></use> </svg> </button> <script src="https://code.jquery.com/jquery-3.5.0.min.js" integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ=" crossorigin="anonymous"> </script> <script type="text/javascript">var exports = {};</script> <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script> <script type="application/javascript"> window.ncbi = window.ncbi || {}; window.ncbi.pmc = window.ncbi.pmc || {}; window.ncbi.pmc.options = { logLevel: 'INFO', staticEndpoint: '/static/', citeCookieName: 'pmc-cf', }; </script> <script type="module" crossorigin="" src="/static/assets/base-9bea7450.js"></script> <script type="module" crossorigin="" src="/static/assets/article-722d91a2.js"></script> </body> </html>

CINXE.COM

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms - PMC